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GENERAL INTRODUCTION
1.1 Lung cancer
In 1761, lung cancer was first described as a distinct disease based on autopsies 
by Giovanni Morgagni.1 In 1810, Gaspard Laurent Bayle described lung cancer in 
more detail in his book entitled Recherches sur la phthisie pulmonaire.2 At that time 
it was an extremely rare disease; in 1878, malignant lung tumors included only one 
percent of all cancers discovered during autopsies at the Institute of Pathology of 
the University of Dresden in Germany. Nowadays lung cancer is the major cause of 
cancer deaths worldwide.3 There are two major groups of lung cancer: non-small-
cell lung cancer (NSCLC) and small-cell lung cancer, accounting for approximately 
85% and 15% of lung cancer cases, respectively.3 NSCLC can be divided into four 
histological subtypes: squamous cell carcinoma, adenocarcinoma, large cell lung 
carcinoma and undifferentiated NSCLC. Squamous cell carcinoma mostly develops 
from bronchial epithelial cells in the central airway, while most tumors that are not 
related to smoking, like adenocarcinoma, develop from basal bronchial cells and 
type II pneumocytes and arise in the more peripheral parts of the lung.4
Although the subdivision of NSCLC has no direct treatment consequences in lim-
ited disease, in advanced disease treatment choices depend on these histological 
differences.5
The 5-year survival of lung cancer is 73% for localized NSCLC and only 13% for 
metastasized disease.6 One of the reasons for this extremely poor survival is that 
most lung cancer cases are diagnosed at an advanced stage due to the relative lack 
of clinical symptoms during early stages. Metastatic NSCLC is currently an incurable 
disease for which standard chemotherapy provides only minor improvement in over-
all survival. Less than 30% of unselected patients with advanced-stage NSCLC have a 
clinical response to platinum-based chemotherapy, which is in general considered to 
be the most effective first line treatment at this stage of the disease.7
1.2 Prognostic factors of lung cancer
1.2.1 Stage of disease
Stage of lung cancer is an important prognostic factor. The 5-year survival rates sig-
nificantly differ between the different subgroups (Table 1). The stage of lung cancer is 
determined based on the characteristics of the 7th revised tumor, node and metastases 
(TNM) criteria, established by the International Associations for the Study of Lung 
Cancer (IASLC) (Table 2). These criteria have defined four major stages of lung cancer. 
The TNM classification can be subdivided in the clinical TNM stage (cTNM) and the 
pathological TNM stage (pTNM). The cTNM is based on the results of a chest X-ray, 
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computer tomography (CT) scan of the chest and upper abdomen, a fluorodeoxyglu-
cose- positron emission tomography (FDG-PET) scan, and/or a magnetic resonance 
imaging (MRI) of the brain, while the pTNM is based on the pathological results of 
a surgical resection. Because the latter is most accurate, there can be differences 
between cTNM and pTNM. Treatment options are determined based on the stage of 
the disease.
1.2.2 World Healthy Organisation (WHO) performance status
WHO performance status is next to the stage of lung cancer the most pivotal inde-
pendent prognostic factor.8 It runs from 0 to 5, with 0 denoting perfect health and 5 
death (Table 3). The 5-year survival rates are significantly different between the five 
categories.9,10 From this it can be concluded that patients will benefit from a diagnosis 
of lung cancer in an asymptomatic stage.
Table 1 Survival of non-small cell lung cancer according to stage of the disease70-72
Lung cancer stage Median survival (months) 5-year survival (%)
IA 59 73
IB 48 58
IIA 30 46
IIB 24 36
IIIA 14 24
IIIB 9 9
IV 4 13
Table 2 Lung cancer staging according to the TNM descriptor and subgroups71,73
T/M Detailed T/M N0 N1 N2 N3
T1 (< 2 cm) T1a IA IIA IIIA IIIB
T1 (> 2-3 cm) T1b IA IIA IIIA IIIB
T2 (> 3-< 5 cm) T2a IB IIA IIIA IIIB
T2 (> 5-7 cm) T2b IIA IIB IIIA IIIB
T2 (> 7 cm) T3 IIB IIIA IIIA IIIB
T3 invasion  IIB IIIA IIIA IIIB
T4 (same lobe nodules)  IIB IIIA IIIA IIIB
T4 (extension) T4 IIIA IIIA IIIB IIIB
M1 (ipsilateral lung)  IIIA IIIA IIIB IIIB
T4 (pleural effusion) M1a IV IV IV IV
M1 (contralateral lung)  IV IV IV IV
M1 (distant) M1b IV IV IV IV
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1.3 Pathogenesis of lung cancer
1.3.1 Risk factors
The most important risk factor for NSCLC is smoking, which account for approxi-
mately 85% of all lung cancer cases.11 In 1929, the German physician Fritz Lickint 
already recognized the link between smoking and lung cancer, which led to an 
aggressive anti-smoking campaign. However, the first major epidemiological study 
about the link between lung cancer and smoking was published by sir Richard Doll 
and sir A. Bradford Hill in 1956.12 Smoking causes all types of lung cancer but is 
most strongly correlated with small-cell lung cancer and squamous-cell lung cancer. 
Adenocarcinoma is the most common type in never smokers.13
Environmental factors and genetic susceptibility interact to influence carcinogen-
esis. Lung tissue injury, from tobacco smoke or other environmental factors, such as 
asbestos, initially occurs in the form of genetic and epigenetic changes, like muta-
tions, loss of heterozygosity and promotor methylation. This can lead to changes in 
the lung tissue, such as inflammation. These changes can persist long term and can 
eventually lead to aberrant pathway activation and cellular function, like dysregu-
lated proliferation and apoptosis. This can cause premalignant changes, including 
dysplasia and clonal patches and can eventually lead to angiogenesis, invasion and 
early-stage cancer.14,15
1.3.2 Genetic risk factors
Epidemiologic studies show an association between family history and increased risk 
of lung cancer. Consequently, multiple studies have been performed on inherited 
predisposition to lung cancer including study of polymorphisms associated with lung 
cancer risk and familial linkage studies. This provides evidence of host susceptibil-
ity. Several independent genome-wide association studies (GWAS) identified single 
nucleotide polymorphism (SNP) variations at 15q24-q25.1 that were associated with 
an increased risk of both nicotine dependence and developing lung cancer.16-18 The 
Table 3 WHO performance score9
WHO-score Description
0 Asymptomatic (Fully active, able to carry on all activities without restriction)
1 Symptomatic but completely ambulatory (Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or sedentary nature)
2 Symptomatic, <50% in bed during the day (Ambulatory and capable of all self care but 
unable to perform any work activities)
3 Symptomatic, >50% in bed, but not bedbound (Capable of only limited self-care)
4 Bedbound (Completely disabled. Not able to perform any self-care)
5 Death
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region of the SNP includes genes encoding nicotinic acetylcholine receptor (nAChR) 
subunits (CHRNA5, CHRNA3, and CHRNB4). More recently, meta-analyses have 
provided further evidence that variation at 15q25.1, 5p15.33, and 6p21.33 influ-
ences lung cancer risk.19 It has not yet been elucidated whether there is a mechanistic 
association with these nAChR polymorphisms and nicotine addiction, carcinogenic 
derivatives of nicotine exposure, or the effect of nicotine acting on nAChRs known to 
be expressed in lung epithelial cells.11
Lung cancer susceptibility also increases when there is a reduced capacity to repair 
DNA, especially in combination with tobacco smoke. This reduced capacity can be 
due to germ-line alterations in nucleotide excision repair genes, such as ERCC1.20 
Next to this there are also inherited cancer syndromes caused by rare germ-line 
mutations in the p53 suppressor gene21, the epidermal growth factor receptor (EGFR) 
gene22 and the retinoblastoma gene.23
1.3.3 Immune system
In the process of carcinogenesis, the tumor-microenvironment and the immune 
system play an important role. Tumor cells can elicit a specific immune response by 
the host through the expression of tumor-associated antigens (TAA). TAA emerge by 
mutations leading to synthesis and overexpression of abnormal proteins. The immune 
system will recognise these TAA and can thereby discriminate between malignant 
cells and other cells. During the early stage of tumor development there are differ-
ent immunological cell types from the innate and adaptive immune system involved 
in the recognition and destruction of tumors. The innate immune system, including 
macrophages, neutrophils, natural killer (NK) cells, NKT cells, gamma-delta T cells 
and certain cytokines (IL-12), plays a role in the early lines of defence, while the 
adaptive immune system plays a more specific role against certain tumor antigens. 
To generate this adaptive immune response, TAA need to be presented to the cells of 
the adaptive immune system. Antigen presenting cells (APC), such as dendritic cells 
(DC) and macrophages, can achieve this. They play a pivotal role in the presentation 
of antigens to cells of the adaptive immune system and can thereby lead to activation 
and differentiation of lymphocytes. APC are cells that originate from bone marrow 
precursor cells. They appear in peripheral tissues where they detect and take up 
foreign substances, including TAA, which are released from dying tumor cells. DC 
will migrate to regional draining lymphoid organs after they captured antigens. The 
antigens are processed and presented by major histocompatibility complex (MHC) 
molecules of the APC. This will lead to antigen-specific activation of lymphocytes. T 
lymphocytes mediate the cellular immunity, while B lymphocytes will mediate the 
humoral immunity, as they are able to produce antibodies. T lymphocytes can be 
divided into at least two major subsets: T helper cells (Th cells) and cytotoxic T cells 
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(CTL). Th cells can stimulate the proliferation and differentiation of B and T cells, and 
CTL are able to kill cells that express foreign antigens, including tumor cells.
Nevertheless, the role of the immune system in carcinogenesis is two-folded; it 
can either suppress tumor expansion by attacking cancer cells or it can activate 
tumor progression by establishing conditions within the tumor microenvironment 
that smooth the progress of tumor development.24 So, there is a complex interaction 
between tumor cells and the immune system with both pro-tumor and anti-tumor 
functions.24
Leukocyte infiltration is an important characteristic of lung cancer and the main 
components of these infiltrates include T and B lymphocytes, tumor-associated mac-
rophages (TAM), myeloid-derived suppressor cells (MDSC), regulatory T-cells (Treg), 
mast cells and natural killer (NK) cells.
Infiltration of mature DC (mDC), cytotoxic CD8 T-cells, M1 type TAM, CD4 T-cells, 
natural killer (NK) cells, neutrophils and possibly Th17 cells will lead to tumor regres-
sion. While, immature DC (iDC), regulatory T cells (Tregs), myeloid-derived suppres-
sor cells (MDSC) and M2 type TAM, will stimulate progression of the tumor.25-29
1.3.4 Tumor immune escape
It has been described that during tumor development tumor cells undergo multiple 
changes to escape the immune surveillance, by either evading the induction of an 
immune response or the inhibition of anti-tumor responses via a variety of mecha-
nisms.30 The mechanisms that can be used are related to the tumor cells whereas 
others act via the interaction with the immune system. One way in which tumor cells 
can avoid recognition by CTL is by downregulation of the MHC class I molecules 
on their cell membrane, as this will lead to a decreased TAA presentation to T cells. 
Tumor cells can also down-regulate the expression of TAA, so there will be no rec-
ognition of foreign antigens by APC. In addition, the TAA can be presented by APC 
to lymphocytes in a tolerogenic form, which will lead to specific immunologic toler-
ance. Next to this, antigents on tumor cells can be hidden from the immune system 
by glycocalyx molecules, such as sialic acid-containing mucopolysaccharides. Tumor 
cells can also induce immunologic tolerance through the expression of programmed 
death ligand-1 (PDL-1), which can inhibit T cells through interaction with the negative 
co-stimulatory receptor PD-1. Another tumor escape mechanism is the production 
of soluble immunosuppressive mediators, including prostaglandin (PGE), interleukin 
(IL)-10, IL-23, vascular endothelial growth factor (VEGF), transforming growth factor 
(TGF)-b. These factors can directly inhibit immune responses, by the suppression of 
APC and T cells. 30
Many of the tumor-derived factors listed above are suppressive and in this way 
create an immunesuppressive environment or they can indirectly induce immune 
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suppressor cells, such as Treg, M2 type TAM or MDSC. The physiological role of these 
cell types is to prevent autoimmunity.31 However, cancer cells take full advantage of 
these cells.
1.4 Early detection of lung cancer
1.4.1 CT-screening
Lung cancer screening aims to detect lung cancer at an early disease stage to improve 
survival of this devastating disease, as the chance of curative treatment is higher 
in limited disease. After several trials showed that chest radiography was unsuc-
cessful, the low-dose multi-detector CT scan has been investigated to reduce lung 
cancer mortality. The advantages of these CT scans are improved spatial resolution, 
the capacity to reconstruct multiple series from a single data acquisition and higher 
scan speed. Several large screening studies showed that high numbers of lung cancer 
could be detected in high-risk patients with CT scan compared to chest radiography 
and that most of these lesions were detected in an early and thus resectable stage.32,33 
The National Lung Screening Trial (NLST) recently showed in a selected population 
that there is a 20% reduction in lung cancer specific mortality in the screened arm, 
compared to the non-screened arm.34
When comparing survival rates, it is important to realize that there are several 
biases, such as lead-time bias, length time bias and overdiagnosis that could play an 
important role. Lead-time bias occurs when testing increases the perceived survival 
time without affecting the course of the disease. Length time bias occurs because 
screening is more likely to detect slow growing tumors than fast growing tumors. 
This can give the impression that screening prolongs survival. However, this is simply 
because slow growing tumors are less aggressive and have a higher chance of being 
detected, but the prolonged survival of the detected tumors is not due to screening.
Overdiagnosis is the diagnosis of a disease that will never have caused symptoms 
or death during a patient’s life. This may unnecessary lead to harm, due to treatment 
and psychological stress.
The clinical applicability of lung cancer CT screening is at present criticized, due 
to important factors that need to be addressed first. This is described in chapter 5.35,36
1.4.2 Blood biomarkers
Another screening method that could lead to early detection of lung cancer is de-
tecting biomarkers of in peripheral blood. A large number of biomarkers have been 
studied, for example the detection of transcriptomics (micro RNA and messenger 
RNA). Micro RNA is a class of small non-coding RNA gene products that can regulate 
certain gene expression. It has been shown that the micro RNA patterns between 
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lung cancer patients and healthy controls are significantly different. Therefore these 
patterns can be used for risk stratification and prediction models. Messenger RNA can 
be used for detecting circulating tumor cells. Recent studies show promising results 
in tracing lung cancer.37-39
Next to messenger RNA, lung cancer might also be detected in the blood based 
on circulating tumor DNA. It has been described that persons with circulating DNA 
levels of > 20 ng/ml have a high chance of having lung cancer, however more studies 
are needed to make the cut-off values more accurate.40
Another blood biomarker that might be useful is the analysis of promoter hyper-
methylation in plasma. It has been shown that lung cancer patients have elevated 
levels of methylated genes in their plasma. Hypermethylation is associated with 
silencing of promoter regions of growth controlling genes and is found in cancer 
cells.41
Currently, blood biomarkers cannot yet be used in daily clinical practice, as most 
studies have not been validated independently and there are still contrary results 
between the different studies. Integration of biomarkers and clinical parameters in a 
model may improve results; therefore more research in this field is needed.
1.4.3 Exhaled breath measurements
The detection of lung cancer in exhaled breath measurements is another interesting 
screening method, especially because it is non-invasive. This method is originally 
based on cancer detection with sniffing dogs42, but better standardisation is expected 
with the ‘electronic nose’. The detection is based on the presence of volatile organic 
compounds (VOC) in lung cancer patients.43 The exhaled breath reflects the meta-
bolic activity in the body, resulting in different VOC profiles between lung cancer 
patients and healthy controls. Recently, studies showed that the exhaled breath could 
moderately distinguish lung cancer patients from control subjects.44,45 The accuracy 
improved when clinical risk factors were taken into account.46
1.4.4 Sputum cytology
Sputum analysis represents a promising tool for early lung cancer detection.47 The 
exfoliative cytology is used to identify the early stage of cancer and to prevent tu-
mor mortality.48 It is thought that lung cancer can be detected based on genetic or 
epigenetic changes in exfoliated cells. Two randomized studies, the Memorial Sloan-
Kettering Lung Study and the Johns Hopkins Lung Project,49 were identically designed 
to evaluate the benefits of sputum cytology to annual chest radiography. No decrease 
in lung cancer mortality rates were seen in the more intensely screened arm of either 
study. However, both studies showed a modest benefit among the heaviest smokers 
and a moderate reduction in deaths due to squamous cell and large cell lung cancer.49
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Another trial, the Mayo Lung Project, provides strong evidence that combining 
sputum cytology and chest X-ray could lead to a higher detection rate.48,50 However, 
these results did not show a mortality benefit from screening: lung cancer-specific 
mortality was 4.4 and 3.9 per 1000 person-years in the screened and control arms, 
respectively, (two-sided P for difference = 0.09).51
It has been described that conventional sputum cytology is an adequate method 
of establishing the diagnosis of lung cancer, with a pooled sensitivity rate of 0.66. In 
addition, the sensitivity of sputum cytology increased to 76% by the use of fluores-
cence in situ hybridization to the conventional sputum cytology.52 So, the addition 
of different techniques to analyze the cytological specimen may improve diagnostic 
values. However, these results should be replicated in larger cohorts before they can 
be used in clinical practice.
1.5 Lung cancer treatment
15.1 General
Currently, lung cancer treatment largely depends on the stage of the cancer. In NSCLC 
patients with stage I and II surgical resection is the treatment of choice and adjuvant 
chemotherapy is optimal in patients with stage II. Radiotherapy remains an important 
treatment for patients that are medically inoperable or refuse surgery.53 Combina-
tion chemoradiotherapy, especially delivered concurrently, is the preferred treatment 
for lung cancer patients with stage IIIA and IIIB. Also surgery may be indicated for 
carefully selected patients with T4N0-1M0.53 The treatment of stage IV NSCLC is pal-
liative with platinum-based doublets as the standard of care in patients with good 
performance score. There is scientific evidence that the addition of bevacizumab, 
an antiangiogenic agent, to carboplatin/paclitaxel in patients with stage IV disease 
improves survival. However, this only works in patients with non-squamous NSCLC.53
1.5.2 Chemotherapy
Lung cancer patients have a high chance of tumor recurrence. Even early stage 
NSCLC patients with complete surgical resection can have undetectable metasta-
ses at diagnosis.54,55 Therefore, several studies have addressed the role of adjuvant 
chemotherapy.7,56 The effect of cisplatin-based chemotherapy was shown in a large 
meta-analysis of stage II patients. They found that cisplatin-based chemotherapy leads 
to a 27% mortality reduction. 57,58
Chemotherapy in patients with stage IV NSCLC and a good performance score 
shows an improved survival and it palliates disease-related symptoms. The role of 
chemotherapy in patients with a poor performance score is less convincing and the 
optimal approach has not yet been determined.59
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1.5.3 Targeted therapy
Recently, new treatment options have become available for NSCLC, which can lead 
to increased survival. These therapies consist of targeted agents. Targeted agents 
block cancer cell growth by interfering with specific targeted molecules needed for 
carcinogenesis and tumor growth, rather than by interfering with all rapidly dividing 
cells, like chemotherapy does.60
One target for these agents is the epidermal growth factor receptor (EGFR, also 
called HER1 or erbB-1) tyrosine kinases (TK). EGFR exists as a monomer on the cell 
surface, and it must dimerize to activate the TK. A significant group of lung cancer pa-
tients have mutations in the EGFR.61 These mutations mostly lead to over expression of 
the EGFR in NSCLC.61 The EGFR regulates important processes in the carcinogenesis 
of cells, like proliferation, apoptosis, angiogenesis, and invasion.62 EGFR treatment 
involves EGFR TK inhibitors, such as erlotinib or gefitinib, or monoclonal antibod-
ies against EGFR, such as cetuximab.62 Erlotinib and gefitinib demonstrated clinical 
activity in patients who had been previously treated with cytotoxic chemotherapy. 
Further study defined clinical and molecular parameters that have enabled the identi-
fication of those who are most likely to benefit from such therapy. Objective response 
rates of 55 to 90 percent were observed in phase II studies with both erlotinib and 
gefitinib when patients were selected based upon molecular criteria.61
Another target for which recently an agent has become available is the transloca-
tion of the echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic 
lymphoma kinase (ALK).4 A subgroup of NSCLC tumors contain an inversion in 
chromosome 2 that juxtaposes the 5’ end of the EML4 gene with the 3’ end of the 
ALK gene, resulting in the novel fusion oncogene EML4-ALK.63 Tumors that contain 
the EML4-ALK fusion oncogene or its variants are associated with clinical features 
quite similar to the patients with EGFR mutations, including never or light smoking 
history, younger age, and adenocarcinoma. ALK gene arrangements are largely mutu-
ally exclusive with EGFR or KRAS mutations.64 In the near future, selection of patients 
with EML4-ALK fusion oncogene will be important, since crizotinib, an ALK targeted 
inhibitor, has shown very promising results in a phase I and III trials.65
1.5.4 Treatment resistance
In most lung cancer cases, specific mutations of the tumor are unknown. In the 
patients with identified tumor mutations, there is the possibility that these mutations 
will modify during treatment because of the genetic instability of the tumor cells.66 
These epigenetic changes could force drug resistance67 and because treatment could 
encourage these changes68, the patients will eventually need to switch to the basic 
treatments as well. Tumors can harbour groups of cells with the same genetic muta-
tions (clones). If the clones dwell in different tumors and reveal differential sensitivity 
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to a treatment, only a mixed treatment response will be observed and the treatment 
must be switched. If two different clones dwell in the same tumor, it is dependent 
on the differential sensitivity of the clones how the response to treatment will be.66,69 
Even though, chemotherapeutic agents can be effective in the treatment of lung can-
cer, most patients will eventually relapse,54 because of an initial intrinsic resistance 
or resistance after initial response to treatment.66,69
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AIMS OF THE THESIS
In the previous chapter, general aspects of lung cancer were described, including 
the limited treatment options and the low survival rates. During the past decades, 
numerous efforts have been made to decrease the death rate among lung cancer 
patients. Nonetheless, the improvement in long-term survival was limited and for 
most lung cancer patients it is still a devastating disease. Recent reports show a de-
crease in lung cancer mortality by screening programs. In addition, modulation of the 
patient’s immune system by immunotherapy either as monotherapy or combined with 
conventional cancer treatments might offer the prospect of tailoring treatments much 
more precisely and might lead to a better response to treatment and overall survival 
of NSCLC patients. Although recently the addition of targeted agents has increased 
survival for advanced disease, it also became clear that tumors develop resistance 
against these agents, either mutation driven or non-mutation driven. Since only small 
improvements in survival can be expected in advanced disease with the use of con-
ventional therapies, more research should focus on lung cancer screening programs 
and patient tailored immunotherapy with or without conventional therapies. This 
thesis evaluates the role of the immune system in lung cancer patients. In addition, 
the role of CT screening to detect early stage lung cancer patients is examined. The 
aims of this thesis are to evaluate the role of new strategies that can improve lung 
cancer survival.
OUTLINE OF THE THESIS
Part I: General introduction and outline of the thesis
Chapter 1 gives a general overview of lung cancer and the aims and the outline of 
the thesis are discussed in chapter 2. In  order to evaluate new strategies to improve 
the survival of lung cancer we describe the role of lung cancer screening and im-
munotherapy in chapter 3. We describe that survival of lung cancer can be strongly 
improved by controlling two prognostic factors: stage and treatment.
Part II: Evaluation of the role of lung cancer screening
In chapter 4 the inclusion criteria of lung cancer screening are discussed regarding 
the generalizability of the findings from large screenings trials to the total population 
of lung cancer patients, to investigate the clinical value. Chapter 5 evaluates the 
applicability of lung cancer screening in more detail. The advantages and limitations 
of screening and the implications of lung cancer survival are here discussed.
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Part III: The contribution of the immune system in lung cancer
Chapter 6 provides an overview of the relevant immunological cell types in lung 
cancer and their complex and dynamic roles within an established tumor microen-
vironment. In chapter 7 we determine the role of specific immune system in lung 
cancer patients. Therefore, we analyzed an important population of immune sup-
pressive cells, myeloid derived suppressor cells (MDSC). In this chapter we describe 
a new receptor on MDSC, named ILT3, which plays a role in suppression of T cell 
responses. In Chapter 8 we describe the composition of the immune system of lung 
cancer patients, therefore we determined the immunological baseline characteristics 
of 185 advanced stage non-small cell lung cancer (NSCLC) patients. In addition, 
we describe the characterization and optimal assessment of MDSC to examine their 
presence and function in the peripheral blood of advanced stage NSCLC patients. 
In chapter 9 we investigate the role of cytotoxic T lymphocytes (CTLs) and MDSC 
in the peripheral blood of NSCLC patients with different prognostic factors. We as-
sessed the relation of the immune cell composition between patients with different 
stages of the disease and the WHO performance categories. Chapter 10 describes the 
relationship between inflammation and lung cancer. We investigate whether a history 
of pulmonary tuberculosis is an independent risk factor for lung cancer survival in 
Caucasian patients.
Part IV: General discussion and summary
In chapter 11 the study results are discussed and the interpretations as well as the 
future directives for further research are given.
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ABSTRACT
Background
During the past decades, numerous efforts have been made to decrease the death rate 
among lung cancer patients. Nonetheless, the improvement in long-term survival has 
been limited and lung cancer is still a devastating disease.
Discussion
With this article we would like to point out that survival of lung cancer could be 
strongly improved by controlling two pivotal prognostic factors: stage and treatment. 
This is corresponding with recent reports that show a decrease in lung cancer mortal-
ity by screening programs. In addition, modulation of the patient’s immune system 
by immunotherapy either as monotherapy or combined with conventional cancer 
treatments offers the prospect of tailoring treatments much more precisely and has 
also been shown to lead to a better response to treatment and overall survival of 
non-small cell lung cancer patients.
Summary
Since only small improvements in survival can be expected in advanced disease with 
the use of conventional therapies, more research should be focused on lung cancer 
screening programs and patient tailored immunotherapy with or without conventional 
therapies. If these approaches are clinically combined in a standard multidisciplinary 
policy we might be able to advance the survival of patients with lung cancer.
KEYWORDS
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- Immunotherapy
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BACKGROUND
Lung cancer is the leading cause of cancer-related death worldwide. Approximately 
85% of all cases of lung cancer are non–small cell lung cancer (NSCLC). The 5-year 
survival of this aggressive disease is only 16%.1 One of the reasons for this extremely 
poor survival is that most lung cancer cases are diagnosed at an advanced stage 
due to the relative lack of clinical symptoms during early stages. Metastatic NSCLC 
is currently an incurable disease for which standard chemotherapy provides only 
minor improvement in overall survival. In addition, less than 30% of patients with 
advanced-stage NSCLC have a response to platinum-based chemotherapy, the most 
commonly used first line treatment at this stage of the disease.2
During the last decades, advances in diagnostic and therapeutic approaches of this 
devastating disease have been made, however, long-term survival rates have hardly 
changed in the past 50 years.3 Therefore, new approaches are required.
DISCUSSION
Survival of lung cancer could be strongly improved by controlling two pivotal prog-
nostic factors: stage and treatment. Early stages of lung cancer have a better prognosis; 
thus early diagnosis of lung cancer by screening programs is one way that leads to a 
reduction in lung cancer mortality. However, given the high chance of tumor recur-
rence, even alleged early stage NSCLC patients with adequate surgical resection can 
have undetectable metastases at diagnosis.4,5 It is known that adjuvant chemotherapy 
can reduce these metastases; nevertheless, in 24% of the patients metastasis occurs 
after adjuvant chemotherapy.4 Therefore, besides lung cancer screening programs, an 
additional approach next to the conventional therapy must be developed to tackle 
lung cancer. In recent years it has been established that the immune system plays 
an important role in carcinogenesis and makes an essential contribution to the anti-
tumor effects of traditional therapies. Modulation of the patient’s immune system 
by immunotherapy either as monotherapy or combined with conventional cancer 
treatments offers the prospect of tailoring treatments much more precisely and could 
lead to a better response to treatment and overall survival of NSCLC patients.
Taken together, when early diagnosis by screening programs and patient-tailored 
immunotherapy are combined in a standard multidisciplinary policy for NSCLC treat-
ment, we might be able to advance the survival of patients with early stage lung 
cancer. We will discuss both topics and their role in improving lung cancer survival 
below.
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Lung cancer screening
Multiple randomized trials have investigated the effectiveness of lung cancer screen-
ing and it is shown that lung cancer can be identified at an early stage with detection 
rates varying between 40-66%.6,7 The survival rates of lung cancer patients diagnosed 
in screening programs are very high; 5- and even 10-year survival rates close to 
90% can be achieved.8,9 The largest lung cancer screening trial10 recently showed 
that screening of high risk persons is very effective in reducing the mortality from 
lung cancer. Persons with more than 30 pack-years (PY) and aged between 55 and 
74 years at time of randomization were included in this study. They found a relative 
mortality reduction of 20% when this high-risk group is screened with a low-dose 
computer tomography (CT) scan compared to chest radiography.10 However, this 
is probably an underestimate, as the mortality reduction was measured at the time 
of closure of the trial. The introduction of low-dose multi-detector CT has led to 
important advantages, such as advanced scan speed, better spatial resolution, and 
the capacity to reconstruct multiple series from a single data acquisition. Before 
public policy recommendations are crafted, there are major concerns in lung cancer 
screening such as the effects of false positive findings, lead-time bias, the impact of 
overdiagnosis, and the generalizability of the results.11
Another important aspect that should be considered in generalizing the results of 
screening studies are the therapeutic options for patients with a positive screening, as 
lung cancer treatment is an important prognostic factor. In developed countries, lung 
cancer patients are treated with surgery, chemotherapy, and radiotherapy. In recent 
years, peri-operative mortality has decreased by the introduction of video assisted 
thoracoscopy (VATS) and better peri-operative management.12 Early stage patients 
who are not eligible for surgery are frequently treated with radiotherapy with curative 
intent. Novel radiotherapy techniques, such as stereotactic ablative radiotherapy, 
show local control rates of 90% or more for stage I NSCLC.13 Adjuvant chemo-
therapeutic regimens have been shown to increase survival especially in resected 
patients with stage II and IIIA disease.14 These regimens are expensive and therefore 
the results of the published screening trials can only be applied to the selected group 
of individuals in countries with well-developed health care systems with a quality 
comparable to the US.
Adjuvant immunotherapy
Treatment of lung cancer is currently based on the patient’s clinical signs and 
symptoms, tumor stage and subtype, medical history, and data from imaging and 
laboratory evaluation. Until now, most cancer research is focused on therapies based 
on tumor characteristics to improve the prognosis of NSCLC, as cancer has long been 
considered as a cell-autonomous genetic disease. However, the sobering outcome 
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of current NSCLC therapy has shifted the attention to combining adjuvant treatment 
approaches.
Recent experimental findings and clinical observations have led to cancer-related 
immune inflammation being acknowledged as a new hallmark of cancer.15-17 Evi-
dence that the immune system of the host can influence cancer incidence, cancer 
growth, response to therapy, and the prognosis of the disease, is growing.18 Therefore 
it was thought that conventional therapy combined with immunotherapy based on 
a pretreatment profile of the immune system of the host could be a valuable tool to 
increase the survival of early stage NSCLC.19
Cancer immunotherapy attempts to activate the host’s immune system to recognize 
and destroy the residual lung cancer cells that conventional therapy misses. Immuno-
therapy can be divided into two main types: passive and active immunotherapy.20,21 
The most common form of passive immunotherapy is monoclonal antibody therapy.20 
It makes use of antibodies that have been produced in vitro and can bind to specific 
cell surface proteins that can influence tumor growth.22 However, there will only be 
a response of the immune system during the time the antibody is present in the body. 
Ipilimumab (anti-CTLA-4), bevacizumab (anti-VEGF), and anti programmed death 
(anti-PD-1) or anti-PD ligand 1 (Anti-PD-L1) are examples of passive immunotherapy 
that could be useful in NSCLC.23-26
Ipilimumab blocks the negative cytotoxic T-lymphocyte antigen (CTLA)-4 that 
enhances T-cell responses to tumor cells, leading to effective immune responses. For 
NSCLC, ipilimumab is now in phase II development 24, but it is already approved 
by the US Food and Drug Administration (FDA) for the treatment of unresectable or 
metastatic melanoma.24,27,28 Studies show that the two- and three-year survival rates 
in ipilimumab-containing treatment arms in metastatic melanoma patients are almost 
twice as high as in the non-ipilimumab-containing treatment arm.
Bevacizumab is an antibody that neutralizes the vascular endothelial growth factor 
(VEGF) ligand. As a result, it will inhibit angiogenesis.29 Moreover, research has shown 
that adding bevacizumab to chemotherapy is associated with afferent vascular dilata-
tion and efferent vascular constriction of tumor vessels that may help concentrate 
chemotherapy at the tumor site. Bevacizumab combined with taxane-platinum che-
motherapy is the first approved antiangiogenic agent for cancer therapy that showed 
increase of progression-free survival and overall survival in first-line treatment of stage 
IV NSCLC.29-30 Recently, data have been published on the immunogenic effect of 
VEGF. VEGF seems to be involved in a number of mechanisms negatively influencing 
the immune system; it makes dendritic cells more tolerogenic, and induces myeloid 
derived suppressor cells. Adding bevacizumab prevents immunotolerance and could 
thereby contribute to a better survival of lung cancer.31,32
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Two other recently described antibodies that could play important roles in passive 
immunotherapy are anti-PD-1 and anti-PD-L1.25,26 PD-1 is a co-inhibitory receptor 
on activated T-cells that plays an important role in immunosuppression. PD-L1, the 
ligand of PD-1, is expressed on cancer cells and is involved in negative regulation 
of immune responses, as they increase apoptosis of T-cells and inhibit CD4 and 
CD8 T-cell activation.25,26 Inhibition of the interaction between PD-1 and PD-L1 can 
improve T-cell responses and mediate antitumor activity. Recent studies show that 
in NSCLC the objective response rates to anti-PD-1 and anti-PD-L1 are 18% and 
10% respectively.25,26 Blockage of both receptors induced durable tumor regression 
and prolonged stabilization of the disease. These findings confirm that the pathway 
between PD1 and PD-L1 could play an important role in therapeutic intervention and 
that it causes an increase in survival of lung cancer patients.
Active immunotherapy tries to persuade and boost immune effector cells in vivo 
against tumor cells through the administration of immune mediators capable of acti-
vating the humoral (antibodies) and cellular (T cells) immune system.33 Therefore the 
duration of this broad response persists for a long time, because of the immunologic 
memory and it is less prone to antigen mutational responses.33 Currently, multiple 
trials are investigating the effectiveness of different lung cancer vaccines.33-36 In 2001, 
one of the first synthetic lung cancer vaccines showed that 16 out of 65 patients 
had an immune response after vaccination, and the median survival time was more 
than doubled (30.6 months, instead of 13.3 months in controls).37 After that, other 
tumor-antigens vaccines, such as Wilms tumor antigen-1 and IDM-2101 were tested 
and showed immunological responses and prolonged survival in patients with lung 
cancer.21,36 Next to synthetic vaccines there are trials that test dendritic cell (DC) 
vaccines.34,38,39 In DC vaccines, tumor associated antigens are used to load immature 
autologous DCs. These DCs are injected into patients to stimulate antigen-specific 
immune responses in lung cancer patients. Different studies have shown biological 
activity of DC vaccines and phase I and II trials report that a group of lung cancer 
patients had therapeutic benefit.34,39,40 Nevertheless, until now, reports about clinical 
applicability are anecdotal.
Other examples of active immunotherapy in lung cancer are natural killer (NK) cell 
transfer and adoptive T cell transfer.41,42
As described above, recent literature provides evidence for many potentially use-
ful immunotherapy combinations. However, these therapies show drastic antitumor 
responses in only small subsets of patients. Currently, there is lack of predictive bio-
markers to rationally choose combinations of immunotherapy for individual patients 
that benefit from these therapies. Therefore, it is necessary to further elucidate the 
mechanisms that are responsible for clinical benefit in small groups of patients and 
identify relevant pre-treatment biomarkers that distinguish responders from non-
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responders. This patient-tailored treatment approach is able to redress the balance 
towards efficacious antitumor responses that can improve the overall survival for 
more patients.
Taken together, passive and active immunotherapy might have an important adjuvant 
role in early stage NSCLC by consolidating responses to conventional therapy and 
thereby leading to increased lung cancer survival rates. However, further research in 
this field is warranted to improve these therapies and to define subsets of responders.
SUMMARY
During the past decades, numerous efforts have been made to decrease the death rate 
among lung cancer patients. Nonetheless, the improvement in long-term survival has 
been limited and lung cancer is still a devastating disease.3
Since only small improvements in survival can be expected in advanced disease 
with the use of conventional therapies, more research should be focused on early 
stage lung cancer. Combining lung cancer screening programs and patient tailored 
immunotherapy with or without conventional therapies should be further explored. If 
these approaches are clinically combined in a standard multidisciplinary policy we 
might be able to advance the survival of patients with lung cancer.
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To the Editor:
The results of the National Lung Screening Trial (NLST) (ClinicalTrials.gov number, 
NCT00047385) (Aug. 4 issue)1 showed that screening of high-risk persons is very 
effective in reducing mortality from lung cancer. Persons with a history of cigarette 
smoking of at least 30 pack-years who were between 55 and 74 years of age at the 
time of randomization were included in this study.
All inhabitants of the Rotterdam suburb of Ommoord who were 55 years of age or 
older were eligible to participate in the Rotterdam Study,2 an ongoing population-
based prospective cohort study in Rotterdam, the Netherlands. A total of 7983 partici-
pants (78% of persons who were invited to participate) were enrolled between 1990 
and 1993 in the first cohort. Between 1990 and 2009, there were 208 deaths due to 
incident lung cancer in this cohort.
When we compare the relative reduction in mortality from lung cancer in the NLST 
with mortality from lung cancer in the Rotterdam Study, we find different results 
because of the strict inclusion criteria used in the NLST.
In our cohort, only 62 cases of lung cancer (29.8% of the total number of cases 
of lung cancer) occurred in subjects who met the criteria of the NLST (in our study, 
persons with unknown smoking history were included in the >30-pack-year group). 
In our study, a total of 12.5% of the patients with lung cancer between 55 and 74 
years of age were never smokers or had a smoking history of less than 30 pack-years 
at baseline, and 57.7% of the patients with lung cancer were older than 74 years. 
Consequently, 70.2% of cases in the Rotterdam cohort would not have been included 
in the NLST.
A relative reduction in mortality from lung cancer of 20%, as shown in the NLST 
would correlate with a reduction in mortality from lung cancer of 6% in the Rot-
terdam Study population (i.e., 0.2×62=12.4 of the 208 persons would not have died 
from lung cancer).
Screening for lung cancer with the inclusion criteria in the NLST reduced mortality 
from lung cancer as compared with the standard of care, but because only a minority 
of patients with lung cancer meet these criteria, clinicians should be cautious in 
generalizing findings to all patients with lung cancer. A reduction in mortality may be 
different in countries with other demographics and health care systems.
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ABSTRACT
Lung cancer is the major cause of cancer-related death worldwide, with a 5-year 
survival of only 16 %. Most lung cancer cases are diagnosed at an advanced incur-
able stage. As earlier stages have a better prognosis, the key to reducing mortality 
could be early diagnosis of the disease. At present, low-dose computed tomographic 
(CT) screening has shown promising data. Lung cancer death rates were reduced 
by 20 % when CT screening is compared to chest radiography in a high-risk group. 
There are many advantages of CT screening in lung cancer, however there are also 
some important issues that should be taken into account. Therefore, the applicability 
of the results to clinical practice is not clear yet. In this Commentary we discuss 
different aspects that play important roles in the balance between harms and benefits 
of screening, including overdiagnosis, availability of treatment options worldwide, 
ethical considerations, costs, and prolonged life expectancy. We conclude that clini-
cians should be cautious in generalizing findings to the total population of smokers 
and take into account that the use of lung cancer screening in clinical practice may 
have limitations.
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Lung cancer is the major cause of cancer-related death in both men and women 
worldwide. The 5-year survival of this aggressive disease is only 16%.1 One of the 
reasons for this extremely poor survival is that most lung cancer cases are diagnosed 
at an advanced stage due to the relative lack of symptoms during early stages. 
Early stages of lung cancer have a better prognosis. Therefore, early diagnosis of 
lung cancer could lead to reduction of lung cancer mortality. Recently, the National 
Lung Screening Trial (NLST)2 showed that lung cancer death rates can be reduced 
by 20% when a high-risk group is screened with a low-dose computer tomography 
(CT) scan compared to chest radiography. The participants of this study comprised 
non-symptomatic persons aged 55-74 years, who had smoked at least 30 pack-years 
(PY) in their lifetime. Participants received a baseline CT and two annual screening 
CTs and were then followed for a median of 6.5 years. The study demonstrated a shift 
in stage at cancer diagnosis as in the screening arm more cases of early stage lung 
cancer and fewer cases of advanced disease were detected. In conclusion, screen-
ing of high-risk individuals led to a better opportunity for curative treatment. The 
International Association for the Study of Lung Cancer (IASLC) recently held a CT 
Screening Workshop after which the Strategic CT Screening Advisory Committee was 
set up.3 This committee is currently engaging professional societies and organiza-
tions who are stakeholders in lung cancer CT screening implementation across the 
globe, to focus on delivering guidelines and recommendations in six specific areas: 
(i) identification of high-risk individuals for lung cancer CT screening programs; (ii) 
develop radiological guidelines for use in developing national screening programs; 
(iii) develop guidelines for the clinical work-up of “indeterminate nodules” resulting 
from CT screening programmers; (iv) guidelines for pathology reporting of nodules 
from lung cancer CT screening programs; (v) recommendations for surgical and 
therapeutic interventions of suspicious nodules identified through lung cancer CT 
screening programs; and (vi) integration of smoking cessation practices into future 
national lung cancer CT screening programs.3
There are many potential advantages of CT screening. Low-dose CT is not only a 
valuable tool to detect lung cancer at earlier stages; it can also be used to monitor 
other causes of morbidity and mortality in heavy smokers, such as ischemic heart dis-
ease and chronic obstructive lung disease (COPD). Early detection of coronary-artery 
calcification could be used to identify patients who are likely to experience ischemic 
heart disease. In addition, early detection of COPD could signify patients with a rapid 
progression of their COPD, leading to an intensive treatment. Screening for other 
causes of morbidity and mortality in heavy smokers might therefore increase the 
cost-effectiveness of screening programs, especially if positioned in multidisciplinary 
programs that provide smoking cessation programs.4 CT scans could also play an 
important role in research to understand the aetiology and pathophysiology of COPD.
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However, major concerns in lung cancer screening are the management of false 
positive findings and the impact of overdiagnosis. Up to 20% of screening tests lead 
to false positive findings. This exposes participants unnecessarily to potentially harm-
ful diagnostic evaluations and psychological discomfort. Overdiagnosis occurs when 
a screening test detects a lung cancer that would otherwise have remained unnoticed, 
either because the disease remains stable, or grows so slowly that the patient dies be-
fore the disease is diagnosed due to other causes. It has been estimated that between 
10% to as much as 25% of screen detected lung cancers may be overdiagnosed 
cases.5 Overdiagnosis in lung cancer screening is a problem, because it is difficult to 
predict which early-stage cancers will ultimately progress and will be the cause of 
death of the patient.
There are different types of lung cancer, all with a different growth and develop-
mental rate, but at present it is not possible to predefine these subgroups in different 
populations. Due to the recent developments in molecular medicine in lung cancer 
increasing knowledge is developing on this subdivision of lung cancer. It is now 
generally accepted that lung cancer consists of a group of cancers with different 
driving mutations. For instance, there are special characteristics, like EGFR muta-
tions, showing a different susceptibility to therapeutic approaches apart from the fact 
that it is also a positive prognostic factor. This heterogeneity of lung cancer entities 
can change screening efficacy. How much this heterogeneity changes on average is 
dependent on the incidence of the different types of cancer and for instance EGFR 
copy number in tumour cells. The distribution between the different lung cancer 
types varies between distinct populations.
Another important issue that has not been clarified following the results of the NLST 
is related to the generalizability of its results to the general population, as most trials 
use very strict inclusion criteria and thereby select only a subset of the individuals. At 
a population level, the observed mortality reduction in the NSLT may vary depending 
on certain factors In case of the NLST the 20% lung cancer mortality reduction and 
the relative risks of harm and other side-effects was measured on a relative scale, 
and therefore it is difficult to extrapolate the effects in lung cancer mortality from 
the NLST to population with a lower and higher incidence. However, from a health-
care point of view absolute numbers are more indicative. At a population level, the 
observed mortality reduction in the NSLT may vary depending the characteristics 
of the screened population. For instance, in case of a more genetically susceptible 
population, the incidence of lung cancer will be higher, even if same smoking criteria 
are applied. Then, the anticipated 20% relative reduction in mortality with screening 
will lead to a higher absolute number of people who will be saved from lung cancer 
deaths. Conversely, the impact of screening will be decreased in countries with a 
population with lower susceptibility for lung cancer. Of course, screening for 
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lung cancer is not considered to be a modifier of the incidence risk, though the ef-
fectiveness of screening may be different between populations and subgroups within 
each population.
Furthermore, extrapolating the NSLT results requires to consider the diagnostic 
accuracy of the screening test. The NLST made use of multidetector scanners with a 
minimum of four channels. Nowadays the available technology even allows measur-
ing the volume of the tumour nodules. However, expensive high-quality CT scans are 
only available in developed countries. In addition, the assessment and interpretation 
of the scans is dependent on the quality of the radiologist. There is a large difference 
in quality of education of medical doctors worldwide.
Nevertheless, the most important aspect that should be considered in generaliz-
ing the results of screening studies are the therapeutic options for patients with a 
positive screening, as lung cancer treatment is an important prognostic factor. In the 
NLST, patients were treated with surgery, chemotherapy, and radiotherapy. In recent 
years, peri-operative mortality has decreased by the introduction of Video Assisted 
Thoracoscopy (VATS) and better peri-operative management. Early stage patients who 
are not eligible for surgery are frequently treated with radiotherapy with curative 
intent. Novel radiotherapy techniques, such as stereotactic ablative radiotherapy do 
increase survival. Adjuvant chemotherapeutic regimens have been shown to increase 
survival especially in resected patients with stage II and IIIA disease. These regimens 
are expensive and therefore the results of the NLST can only be applied to countries 
with health care systems with a quality comparable to the US.
An additional pivotal public health policy concern in lung cancer screening is 
whether it is ethical to limit screening programs to individuals with >30 PYs of smok-
ing, while approximately one-third of the population of lung cancer patients has 
smoked less than this threshold.6 Screening programs may therefore unintentionally 
give the reassurance that there is no need to stop smoking, leading to continuation 
of smoking.
Also the cost effectiveness of low dose CT screening must be considered. The use 
of three annual CT screenings, the follow-up of the participants and the additional 
clinical procedures in response to positive screening is very expensive: $725,000 
to prevent one death from lung cancer.7 Several research groups modelled the cost-
effectiveness analyses of CT screening with varying conclusions.8-9 Wisnivesky et al.8 
conclude that the cost-effectiveness ratio of a baseline CT scan is within the range 
of clinical practice and health policy acceptability, while Mahadevia et al.9 state 
that lung cancer screening is unlikely to be highly cost-effective without substantial 
reductions in mortality, high rates of adherence, lower rates of overdiagnosis, and 
lower costs per screening test. This contradiction should be investigated in more 
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detail. Existing risk prediction models are approximately 70% accurate in identifying 
higher risk individuals who may benefit most from screening.
We have previously shown that in a large prospective population-based cohort 
study, the Rotterdam Study, only 62 lung cancer cases (30%) fulfilled the NSLT 
inclusion criteria.10 Consequently, when we applied NLST’s relative reduction in 
lung cancer mortality to the Rotterdam Study, we find that the relative reduction in 
mortality of 20%, would lead to an absolute reduction in lung cancer mortality in 
the Rotterdam Study population of 6.0% . This means that 12 persons out of the total 
208 lung cancer deaths found in the Rotterdam Study would have been saved from 
mortality by lung cancer. This difference is mainly due to applying the age restriction, 
as 58% of incident lung cancer cases in the Rotterdam Study were above 74 years. 
In addition, recent literature shows that the highest lung cancer incidence rates were 
among persons aged 70-79 years.11
In the last decade there has been a consistent increase in life expectancy, of 
which two-third is caused by declines in mortality among those aged 65 years and 
older.12 This is partly due to improvements in health care delivery, particularly for the 
elderly.12 Recent evidence suggests that after infectious diseases have largely been 
eliminated as a cause of death, medical care, i.e. a more active approach towards the 
treatment of seriously ill elderly patients, plays the central role for further increases in 
life expectancy.13 Nowadays, there is an increased number of possibilities for curative 
therapeutic interventions in the elderly with lung cancer such as minimal invasive 
surgery and advanced radiotherapy. Taking into account that persons between 70-79 
years have the highest lung cancer risk, life-expectancy in the elderly is increasing 
and curative therapeutic options are available, screening may reduce lung cancer 
mortality, also in this population. A possibility is adjusting the age limits in screening 
trials from 74 years to at least 79 years. The effects of this on cost-effectiveness have 
to be determined similar to lung cancer screening in the present studies, taking into 
account prevention of other causes of mortality such as ischemic heart disease.
In conclusion, early detection of lung tumours by lung cancer screening programs 
has led to more curative therapeutic options for patients and to a mortality reduction 
of 20%. There can be no doubt about the importance of such screening programs. 
However, results from the trial may only apply to individuals with access to high 
quality lung cancer care. In addition, screening trials for lung cancer only include a 
minority of lung cancer patients as most patients do not comply with these criteria. 
Therefore, clinicians should be cautious in generalizing findings to the total popula-
tion of smokers and take into account that the use of lung cancer screening in clinical 
practice may have limitations in reducing lung cancer mortality.
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ABSTRACT
Cancer research has devoted most of its energy over the past decades on unravel-
ing the control mechanisms within tumor cells that govern its behavior. From this 
we know that the onset of cancer is the result of cumulative genetic mutations and 
epigenetic alterations in tumor cells leading to an unregulated cell cycle, unlimited 
replicative potential and the possibility for tissue invasion and metastasis. Until re-
cently it was often thought that tumors are more or less undetected or tolerated by 
the patient’s immune system causing the neoplastic cells to divide and spread without 
resistance. However, it is without any doubt that the tumor environment contains a 
wide variety of recruited host immune cells. These tumor infiltrating immune cells 
influence anti-tumor responses in opposing ways and emerges as a critical regulator 
of tumor growth. Here we provide a summary of the relevant immunological cell 
types and their complex and dynamic roles within an established tumor microenvi-
ronment. For this, we focus on both the systemic compartment as well as the local 
presence within the tumor microenvironment of late-stage non-small cell lung cancer 
(NSCLC), admitting that this multifaceted cellular composition will be different from 
earlier stages of the disease, between NSCLC patients. Understanding the paradoxical 
role that the immune system plays in cancer and increasing options for their modula-
tion may alter the odds in favor of a more effective anti-tumor immune response. We 
predict that the future standard of care of lung cancer will involve patient-tailor-made 
combination therapies that associate (traditional) chemotherapeutic drugs and bio-
logicals with immune modulating agents and in this way complement the therapeutic 
armamentarium for this disease.
KEYWORDS
Lung cancer, Tumor microenvironment, Immune system, Personalized medicine, 
Cancer immunology
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REVIEW
Current NSCLC treatment
Treatment of lung cancer is currently based on the patient’s clinical signs and symp-
toms, tumor stage and subtype, medical and family history, and data from imaging 
and laboratory evaluation. Most conventional cancer therapies, such as radiotherapy 
and chemotherapy are restricted by adverse effects on normal tissue. Currently 
NSCLC therapy is moving towards personalized medicine where the genetic profile 
of each patient’s tumor is identified and specific therapies that inhibit the key targets 
of the oncogenic activation are targeted. In approximately 60% of all NSCLC cases, 
specific mutations can be identified, of which ± 20% can be targeted with specific 
drugs at this moment (e.g. erlotinib, gefitinib, crizotinib). However, most patients 
receiving conventional cancer treatments or targeted drugs will experience a relapse 
of tumor growth at a certain time. This sobering outcome demonstrates the necessity 
of innovative approaches in NSCLC treatment.
Recently, experimental findings and clinical observations have led to cancer-related 
immune inflammation being acknowledged as an additional hallmark of cancer [1,2]. 
There is currently overwhelming evidence that several immunological cell types of 
the host influence cancer incidence, cancer growth, response to therapy and thereby 
the prognosis of the disease. However, the immune system plays a paradoxical role 
by either preventing cancer growth or in sculpting tumor escape and stimulates its 
development. A better understanding of the interaction between cancer cells and 
host immune cells within the tumor environment is of importance for further progress 
in cancer treatment. This is an extremely difficult task because of the complicated 
cancer-host immune interactions. The field that studies these interactions, termed 
cancer immunology, is rapidly progressing. It provides insights into the contribu-
tion of the immune system in processes such as tumor invasiveness, metastasis, and 
angiogenesis and may predict the response to treatment. Most importantly, it also pro-
vides opportunities for improved anti-cancer therapies. Modulation of the patient’s 
immune system combined with anti-tumor treatments offers the prospect of tailoring 
treatments much more precisely and better efficacy for patients with advanced lung 
cancer.
Immune cells involved in tumorogenesis
The individual immune related tumor infiltrating cell types are discussed below 
(Figure 1).
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Figure 1: The tumor microenvironment is a heterogeneous and complex system of tumor cells (black) 
and ‘normal’ stromal cells, including endothelial cells and their precursors, pericytes, smooth-muscle 
cells, and fibroblasts of various phenotypes, located within the connective tissue or extra-cellular 
matrix (e.g. collagen). Leukocyte infiltration is an important characteristic of cancer and the main 
components of these infiltrates include natural killer (T) cells, neutrophils, B- and T-lymphocyte 
subsets, myeloid derived suppressor cells, macrophages and dendritic cells 3-7. Based on their 
functions, these cells can be divided into cells with a potentially positive impact on the antitumor 
response (right) and cells with a detrimental effect (left). From mast cells and T helper 17 cells it is 
yet ambiguous what kind of effect these cells have within the micro-environment. The net effect of 
the interactions between these various cell types and their secreted products within the environment 
of an established tumor participates in determining anti-tumor immunity, angiogenesis, metastasis, 
overall cancer cell survival and proliferation.
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Natural killer (T) cells
Natural killer (NK) cells (expressing the surface markers CD16 and CD56, but not 
CD3) are lymphocytes that play an important role in the rejection of tumors with-
out previous sensitization and without restriction by the major histocompatibility 
complex (MHC) [8,9]. NK cells eradicate tumors through multiple killing pathways, 
including direct tumor cell killing. They also secrete cytokines and chemokines like 
Interleukin (IL) IL-10, Tumor Necrosis Factor (TNF)-α, and the principal NK-derived 
cytokine Interferon (IFN)-γ, which can coordinate the innate and adaptive immune 
responses to tumor cells and may lead to apoptosis of the attacked cells.
A large cohort study showed that an increase in NK cells in tumor tissue is a strong 
independent prognostic factor for the survival of lung cancer patients [10]. This is 
confirmed in mouse models, showing that stimulation of NK cell function protected 
against NSCLC metastasis [11,12], while depletion enhanced lung cancer metastasis 
[13]. However, it was recently shown that although the frequencies of NK cells in 
blood do not differ from healthy controls, stimulated blood NK cells from NSCLC 
patients with advanced disease had a reduced granzyme B and perforin A expression, 
lower production of IFN-γ, and decreased cytotoxic function indicating that these 
cells are functionally impaired in comparison with healthy controls [14,15]. Adoptive 
transfer of allogeneic, in vitro activated and expanded NK cells from haploidentical 
donors was proven potentially clinically effective in NSCLC [16].
Natural killer T (NKT) cells (CD16+, CD56+, CD3+) are a subset of NK cells that 
have been found in the peripheral blood, tumor tissue and pleural effusions of lung 
cancer patients in decreased numbers and with reduced functions [17,18]. It has 
been shown that NKT cells in cancer patients produce a decreased amount of IFN-γ 
and are therefore less effective than NKT cells in healthy controls [19,20]. They are 
currently exploited for cancer treatment by harnessing these cells with CD1d agonist 
ligands [21,22], or by adoptive transfer of NKT cells activated in vitro [23].
Mast cells
Accumulation of mast cells is common in angiogenesis-dependent conditions, like 
cancer, as mast cells are a major provider of proangiogenic molecules vascular en-
dothelial growth factor (VEGF), IL-8, transforming growth factor (TGF)-b [24]. The 
density of mast cells in NSCLC tumors is correlated with microvessel density [25] 
and mast cells / histamine has a direct growth promoting effect on NSCLC cell lines 
in vitro [26]. However, the role of mast cells in the prognosis in NSCLC remains con-
troversial [25,27–29]. Tumor-infiltrating mast cells can directly influence proliferation 
and invasion of tumors, by histamine, IL-8 and VEGF while the production of TNF-α 
and heparin can suppress tumor growth [26,30]. It has been shown that in NSCLC 
mast cell counts were noted to increase as tumor stage increased while another study 
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did not show this correlation [24,29]. Mast cells also play a central role in the control 
of innate and adaptive immunity by interacting with B and T cells (in particular Treg) 
and dendritic cells. The controversy of mast cells in cancer seems to be related to the 
type, microenvironment and stage of cancer and their role may depend on the tumor 
environment [29,31,32]. Therapeutic intervention by targeting mast cells, although 
technically possible [33], is too early without more knowledge on the paradoxical 
role of these cells in individual cases.
Neutrophils
Neutrophils play a major role in cancer biology. They make up a significant portion 
of the infiltrating immune cells in the tumor and the absolute neutrophils count and 
the neutrophils to lymphocyte ratio in blood are independent prognostic factors for 
survival of NSCLC [34–36]. Neutrophils are attracted to the tumor under the influence 
of specific chemokines, cytokines and cell adhesion molecules. Tumor-associated 
neutrophils (TAN) have polarized functions and can be divided into the N1 and N2 
phenotype in a context-dependent manner [37,38]. The N1 phenotype inhibits tumor 
growth by potentiating T cell responses while the N2 phenotype promotes tumor 
growth [3]. The antitumor activities of N1 neutrophils include expression of immune 
activating cytokines (TNF-α, IL-12, GM-CSF, and VEGF), T cell attracting chemokines 
(CCL3, CXCL9, CXCL10), lower expression of arginase, and a better capacity of 
killing tumor cells in vitro. N2 neutrophils support tumor growth by producing angio-
genic factors and matrix-degrading enzymes, support the acquisition of a metastatic 
phenotype, and suppress the anti-tumor immune response by inducible nitric oxide 
synthase and arginase expression. Neutrophils also influence adaptive immunity by 
interacting with T cells [39], B-cells [40], and DC [41]. In resectable NSCLC patients, 
intratumoral neutrophils were elevated in 50% of the patients and this was associated 
with a high cumulative incidence of relapse [42]. Recently, Fridlender et al. showed 
that TGF-b acquired the polarized N2 tumor promoting phenotype of neutrophils in a 
murine lung cancer model, and blocking of TGF-b shifted towards N1 tumor rejecting 
neutrophils with acquisition of anti-tumor activity in vitro and in vivo [43]. Blockade 
of TGF-b in humans might be a potential utility to prevent polarization towards the 
protumorigenic N2 phenotype and thereby may result in retarding tumor growth.
B-lymphocytes
B-cells may affect the prognosis of patients with lung cancer, as patients with stage I 
NSCLC contain more intratumoral germinal centers with B-lymphocytes than patients 
with stages II to IV [44]. These tertiary (T-BALT) structures provide some evidence of 
an adaptive immune response that could limit tumor progression in some patients. 
For instance, the production of antibodies by B-cells can activate tumor cell kill-
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ing by NK cells and other inflammatory cells [45]. Auto-antibodies against tumor 
antigens are commonly found in patients with lung cancer [46–48] and can inhibit 
micrometastasis [49]. Recently, it has been shown in mice that antibodies produced 
by B cells interact with and activate Fcγ receptors on macrophages and in this way 
orchestrate antitumor activity [50] or tumor-associated macrophages (TAM)-mediated 
enhancement of carcinogenesis [51]. Thus, the role of B cells seems depending on 
the context.
CD4+ and CD8+ lymphocytes
CD4+ cells and CD8+ cells represent the strong effectors of the adaptive immune 
response against cancer [52]. There is controversy on the impact of T cells and their 
localization on the prognosis of lung cancer [53–59]. This may be caused by the 
presence of a special subset of T cells, the regulatory T cells, and myeloid-derived 
suppressor cells which are discussed below. Also tumor-derived factors can exhaust T 
lymphocytes or induce their apoptosis [60]. Recently it has been shown that cytotoxic 
T lymphocytes (CTL) within the tumor (the tumor-infiltrating lymphocytes [TIL]) are of 
beneficial prognostic influence in resected NSCLC patients in both adenocarcinoma 
[61] and squamous cell carcinoma [62]. Tumor-specific CD8+ effector T-cells are 
normally present at a low frequency in cancer patients, but can be expanded up to 
50% of the total circulating CD8+ T-cells by dendritic cell vaccination or adoptive T-
cell transfer therapy [63–65]. To enhance existing anti-tumor responses, recombinant 
CD40 ligand or CD40 activating antibodies are investigated as substitute for CD4+ T 
cell help [66]. Blocking T cell inhibitory molecules such as cytotoxic T lymphocyte 
antigen-4 (CTLA-4), lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin 
mucin-3 (TIM-3), and programmed death-1 (PD-1) are currently investigated in 
NSCLC to improve T cell homing and effector functions [67,68]. Successes of these 
experimental therapies in small subsets of patients demonstrate that CTL can be di-
rected against the tumor but mechanisms to induce CTL or overcome the inactivation 
of T cell function seems necessary to enable more patients from these treatments.
Regulatory T cells
Regulatory T cells (Treg), characterized by CD4+, CD25+, Foxp3+, and CD127-, are T 
lymphocytes that are generated in the thymus (natural Treg) or induced in the periph-
ery (induced Treg) when triggered by suboptimal antigen stimulation and stimula-
tion with TGF-b and IL-10 [69]. Treg are further characterized by the expression of 
glucocorticoid-induced TNF-receptor-related-protein (GITR), lymphocyte activation 
gene-3 (LAG-3), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).
In cancer patients, Treg confer growth and metastatic advantages by inhibiting 
anti-tumor immunity. They have this pro-tumoral effect by promoting tolerance via 
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direct suppressive functions on activated T-cells or via the secretion of immunosup-
pressive cytokines such as IL-10 and TGF-b [70,71]. Treg are present in tumor tissue 
[72,73] and increased in peripheral blood of NSCLC patients compared to healthy 
controls [74,75]. This increase in Treg was found to promote tumor growth and was 
correlated with lymph node metastasis [56,73,76,77] and poor prognosis [73,78]. 
Many factors can increase Treg in NSCLC tumors, among them are thymic stromal 
lymphopoietin (TSLP) [79] and intratumoral cyclooxygenase-2 (COX-2) expression 
[80]. Treg are considered the most powerful inhibitors of antitumor immunity [81]. 
As a result, there is substantial interest for overcoming this barrier to enhance the 
efficacy of cancer immunotherapy. Strategies include I). Treg depletion by chemi-
cal or radiation lymphoablation or using monoclonal antibodies or ligand-directed 
toxins (daclizumab, basiliximab, denileukin diftitox [OntakTM], RFT5-SMPT-dgA, 
and LMB-2) or with metronomic cyclophosphamide. II). Suppression of their func-
tion (ipilimumab, tremelimumad [anti-CTLA4], DTA-1 [anti-GITR], denosumab 
[anti-RankL], modulation of Toll-like receptor, OX40 stimulation or inhibiting ATP 
hydrolysis using ectonucleotidase inhibitors). III). Inhibition of tumoral homing by 
blocking the selective recruitment and retention of Treg at tumor sites, e.g. CCL22, 
CXCR4, CD103, and CCR2. IV). Exploitation of T-cell plasticity by modulating IL-
6, TGF-b, and PGE2 expression, e.g. the COX-2 inhibitor celecoxib [82]. Till now, 
a strategy that specifically target only Treg and no effector T cells is lacking and 
procedures that depletes or modulates all Treg should be avoided to minimize the 
risk of autoimmune manifestations. However, studies modulating Treg in patients are 
providing some early encouraging results supporting the concept that Treg inhibitory 
strategies have clinical potential, particularly in those therapies that simultaneously 
stimulate antitumor immune effector cells
Gamma delta T cells
Human γδ-T cells constitute 2-10% of T cells in blood and exhibit natural cytolytic 
activity in an MHC-unrestricted manner for microbial pathogens and tumor cells. A 
special TCR on γδ-T cells recognizes small nonpeptide antigens with a phosphate 
residue and isopentenylpyrophosphate (IPP) that accumulate in tumor cells [83]. 
Because γδ-T cells recognize target cells in a unrestricted manner, they may exert 
antitumor effects even on tumor cells with reduced or absent expression of HLA and/
or tumor antigens or by provision of an early source of IFN-γ [83,84]. Phase I clinical 
trials of in vivo activation of γδ-T cells with zoledronic acid plus IL-2 or adoptive 
transfer of in vitro expanded γδ-T cells are being conducted at present for lung cancer 
[85–87].
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Th17 cells
Th17 cells are a subpopulation of CD4+ T helper cells that are characterized by the 
production of interleukin-17 (IL-17, also known as IL-17A). IL17 plays an important 
role in the host defenses against bacterial and fungal infections by the activation, 
recruitment, and migration of neutrophils [88,89]. In vitro experiments have shown 
that IL-1b, IL-6, and IL23 promote Th17 generation and differentiation from naïve 
CD4+ T cells [90]. Among the other cytokines secreted by Th17 cells are IL-17 F, 
IL-21, IL-22, and TNF-α. The role of Th17 cells in cancer is poorly understood. Th17 
cells accumulate in malignant pleural effusion from patients with lung cancer [90]. 
Also higher levels of IL-17A were detected in serum and in tumor lesions of lung 
adenocarcinoma patients, indicating a potential role of these cells in cancer [91]. 
It has been shown that Th17 cells encouraged tumor growth by inducing tumor 
vascularization or enhancing inflammation, but other studies revealed also opposite 
roles for Th17 cells. Recent data indicate that IL-17 may play a role in the metastasis 
of lung cancer by promoting lymphangiogenesis and is therefore an independent 
prognostic factor in both overall and disease-free survival in NSCLC [92]. However, 
there is a distinct role for Th17 and Th17-stimulated cytotoxic T-cells in the induction 
of preventive and therapeutic antitumor immunity in mice by the promoted recruit-
ment of several inflammatory leukocytes, like DC, CD4+ and CD8+ cells [93]. So, it 
is controversial whether Th17 cells in cancer are beneficial or antagonistic; this may 
be dependent on the tumor immunogenicity, the stage of disease, and the impact of 
inflammation and angiogenesis on tumor pathogenesis [94].
Myeloid-derived suppressor cells
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of im-
mature myeloid cells and myeloid progenitor cells. MDSC inhibit T cells activation 
[95,96] in a nonspecific or antigen-specific manner, alter the peptide presenting abil-
ity of MHC class I molecules on tumor cells [97], influence B-cells [98], block NK cell 
cytotoxicity [99–101], inhibit dendritic cell differentiation [102], and expand Treg 
[103,104] signifying their crucial contribution in constituting a tumor suppressive 
environment. Furthermore, there is compelling evidence that MDSC, by secreting 
MMP9 and TGF-b1, are also involved in angiogenesis, vasculogenesis, and metastatic 
spread [105].
MDSC suppress the immune system by the production of reactive oxygen species 
(ROS), nitric oxide (NO), peroxynitrite and secretion of the cytokines IL-10 and TGF-b 
[106]. Upregulated arginase-I activity by MDSC depletes the essential amino acid 
L-arginine, contributing to the induction of T cell tolerance by the down regulation 
of the CD3ζ chain expression of the T cell receptor [107–110]. However, the mecha-
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nisms that are used to suppress the immune responses are highly dependent on the 
context of the microenvironment [111].
An increased subpopulation of MDSC in the peripheral blood of NSCLC patients 
was detected that decreased in those patients that responded to chemotherapy and 
patient undergoing surgery [112]. Because MDSC play an important role in mediating 
immunosuppression, they represent a significant hurdle to successful immune therapy 
in NSCLC. Therefore, targeting MDSC in vivo with drugs like 5-fluorouracil (5FU), 
gemcitabine or VEGF / c-kit blockers (e.g. sunitinib, imatinib, dasatinib) to elicit more 
potent anticancer effects is an exciting development [113–115]. Treatment of mice 
with all-trans retinoic acid (ATRA), along with NKT help, convert the poorly immu-
nogenic MDSC into fully efficient APC and in this way reinforced anti-tumor immune 
responses [116]. Other MDSC suppressing or differentiation-inducing agents recently 
reported are 5-aza-2′-deoxycytidine, curcumin, IL-10, anti-IL4R aptamer, and vitamin 
D3 [117–120]. Agents that decrease arginase activity, ROS and/or iNOS expression 
by MDSC include Nor-NOHA, 1-NMMA, cyclooxygenase 2 inhibitors (celecoxib 
[121]), phosphodiesterase 5 inhibitors (sildenafil, tadalafil [122]) or reactive oxygen 
species inhibitors (nitroaspirin [123]). These agents promise to be a fruitful avenue 
of investigation in the coming years to overcome immune suppression associated by 
MDSC in advanced tumors [113,114].
Tumor–associated macrophages
Macrophages are part of the innate immune system and play important roles in the 
first line of defense against foreign pathogens. They can be divided into M1 mac-
rophages (classical activation) and M2 macrophages (alternative activation). M1 
macrophages attract and activate cells of the adaptive immune system and have 
anti-tumor and tissue destructive activity, while the M2 phenotype has been linked 
to tumor-promoting activities by subversion of adaptive immunity, promoting tumor 
angiogenesis and supporting cancer cell survival, proliferation, invasion and tumor 
dissemination. Macrophages in tumors are usually referred to as tumor-associated 
macrophages (TAM) and their presence can be substantial (10 to 65% of the tumor 
stroma). In the beginning, the TAM mainly consist of M1-like macrophages however, 
when the tumor starts to invade and vascularize, there is a skewing towards the M2 
phenotype [124,125]. This takes place especially at those regions in the tumor that 
are hypoxic [126].
It has been reported by several groups that there is an association between the 
number of tumor islet macrophages and NSCLC survival [58,127–132]. Moreover, 
when looking at the different phenotypes of TAM (M1 and M2), it is shown that 
high numbers of M1 macrophages infiltrating the tumor are correlated with improved 
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survival [130,133]. On the other hand, the presence of M2-like macrophages is as-
sociated with poor clinical outcome [130,133].
Several strategies are currently investigated that influence M2 macrophages at 
multiple levels. For example, blockade of factors and cytokines secreted by tumor or 
immune cells to limit the induction of M2 macrophages are investigated [134–136], 
however this results in loss of typical M2 markers but not their function [137]. It has 
been shown that inhibiting IκB kinase (IKK) reprograms the M2 phenotype to the M1 
subset [138,139]. Also CD40 therapy seems to skew tumor-infiltrating macrophages 
towards the M1 phenotype [140]. Influencing the attraction, the polarization or the 
activation of M2 macrophages may improve survival when combined with standard 
or other immunotherapeutic regimens.
Dendritic cells
Dendritic cells (DC) are widely acknowledged as the central surveillance cell type and 
play an important role in the activation of lymphocyte subsets to control or eliminate 
human tumors. Upon encountering tumor cells or tumor-associated antigens, DC 
engulf this material and begin migrating via lymphatic vessels to regional lymphoid 
organs. The density immature DC (Langerhans cell and interstitial DC) and mature 
DC, present in the tumor microenvironment is highly predictive of disease-specific 
survival in early-stage NSCLC patients [141] and the presence of DC in resected 
NSCLC material is a good prognostic factor [10,142]. Interaction between the DC 
and tumor cells results in the release of antitumour cytokines [143,144]. This suggests 
that DC within the tumor microenvironment of early-stage NSCLC are capable in 
initiating adaptive immune responses in situ [145–147].
In the peripheral blood and regional lymph nodes of lung cancer patients, the 
number and function of mature DC is dramatically reduced [148,149], partly due to 
abnormal differentiation of myeloid cells (e.g. MDSC) [150]. Tumor cells, stromal cells 
like fibroblasts, and tumor-infiltrating immune cells and/or their secreted products, 
like VEGF, M-CSF, IL-6, IL-10, and TGF-b are also responsible for systemic and local 
DC defects [151–154]. Affected DC are impaired in their ability to phagocytose anti-
gen and to stimulate T cells, leading to a defective induction of anti-tumor responses.
NSCLC-derived DC produce high amounts of the immunosuppressive cytokines IL-
10 and TGF-b [155]. It has been shown that the T cell co-inhibitory molecule B7-H3 
and programmed death receptor-ligand-1 (PD-L1) are upregulated on tumor residing 
DC and these molecules conveys mainly suppressive signals by inhibiting cytokine 
production and T cell proliferation [156,157].
Tumor-induced modulation is one of the main factors responsible for tumor im-
mune escape and correction of DC function might be a requirement to develop more 
effective immunotherapeutic strategies against cancer. This might include targeting of 
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those factors with neutralizing antibodies (e.g. anti-VEGF, anti-IL-6) to revert some of 
the inhibitory effects on DC. Another interesting finding is that culturing monocytes 
from cancer patients ex vivo, to circumvent the suppressive activity of the tumor 
milieu, generates DC with a capacity to stimulate allogeneic T cells [158,159]. [160] 
This finding is important for active DC-based immunotherapeutic approaches, where 
DC are generated ex vivo from monocytes and after arming with tumor-associated 
antigens, reinjected into the patient with the intension to restore proper presentation 
of tumor associated antigens (TAA) and T cell activation [161–163]. This concept 
is currently tested for NSCLC in therapeutic reality with encouraging results on the 
immune response, safety and tolerability, despite the small sample sizes of the trials 
[161–163].
Immunogenic cell death biomarkers
Lung cancer is a complex disease with limited treatment options, mainly caused by 
the close relationship between neoplastic cells and healthy cells. To develop a more 
effective treatment for lung cancer, we have to focus on the complex interactions that 
tumor cells have with the local stromal compartment and the involved immune cells, 
and all of their secreted factors. There is growing evidence that the efficacy of many 
traditional therapeutic treatments depends on their ability to induce proper immu-
nogenic tumor cell death. This specific release of signals upon tumor cell death may 
lead to immune activation, and in particular anti-tumor immunity, that contribute to 
the therapeutic outcome for patients [164,165].
There are different candidate immune biomarkers that can predict the efficacy 
of specific NSCLC anticancer therapies [166,167]. In NSCLC, nucleosomes have 
already been proven useful for the early estimation of response to chemotherapy 
[168–170]. Presence of mature dendritic cells and CD4+ or CD8+ lymphocytes in 
NSCLC tumors are independent prognostic factors for overall survival, as described 
above [55,59,171,172]. In addition, other potentially pivotal markers for lung can-
cer are p53-specific autoantibodies and pyridoxal kinase (PDXK), the enzyme that 
generates the bioactive form of vitamin B6 [173]. Also a group of immunogenic cell 
death biomarkers called damage-associated molecular pattern (DAMP) molecules, 
can serve as prognostic markers for response to therapy and prognosis in cancer 
patients [174]. DAMPs, such as surface-exposed calreticulin (ecto-CRT) and the high-
mobility group box 1 protein (HMGB1); are released in the blood circulation by late 
apoptotic and necrotic cells upon oxidative and endoplasmic reticulum (ER) stress. 
In peripheral blood, they bind to specific immune cells and trigger protective T cell 
responses and promote phagocytosis. One of the main functions of HMGB1 is the 
binding to specific receptors on dendritic cells and other antigen presenting cells, 
such as receptors for advanced glycation endproducts (RAGE) and toll-like receptors 
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4 (TLR4). It has been described that the release of DAMP during cell death is essential 
for the sustained therapy response after chemotherapy and the efficiency of HMGB1 
was found to be increased when bacterial lipopolysaccharide (LPS), DNA or nu-
cleosomes were bound to it. Knockdown of HMGB1 was observed to be associated 
with reduced anticancer immune response and poor therapy outcome. In contrary, 
overexpression of HMGB1 and its receptor RAGE is pivotal for the metastasizing of 
the tumor cells as it promotes neoangiogenesis [175]. Markers of immunogenic cell 
death are becoming a valuable tool in clinical practice for diagnosis and prediction 
of response to NSCLC therapy and prognosis [167].
Next to DAMP, there are other approaches using RNA- and DNA-based immune 
modifiers to augment cancer therapy efficacy by stimulating the immune system. 
Bacterial DNA is immunostimulatory and can be replaced using synthetic oligo-
deoxynucleotides (ODN), for instance CpG oligodeoxynucleotides. CpG ODN are 
synthetic DNA sequences containing unmethylated cytosine-guanine motifs with 
potent immune modulatory effects via TLR 9 on DC and B cells [176]. They can 
induce cytokines, activate NK cells, and elicit T cell responses that lead to strong 
antitumor effects. It has been shown that CpG ODN downregulates regulatory T cells 
and TGF-b in peripheral blood of NSCLC patients [177].
Overall, analysis of new and conventional therapeutic strategies should not only 
be focused on the direct cytotoxic effects of tumor cells but also on the initiation of 
proper immune responses. Simultaneous modulation of the immune system by im-
mune therapeutic approaches can then induce synergistic anticancer efficacy [178]. 
Overall, the composition of the immunological cells and cell death markers in the 
host is, next to the mutation analysis and histological features of the tumor, likely to 
determine the response to specific chemotherapeutic agents and the prognosis of the 
patients.
CONCLUSION
In this review, we have shown that the immune system plays a dual role in cancer 
development and progression and determines the response to treatment in NSCLC. 
These complex interactions between diverse immune cell types and tumor cells that 
can actively favor tumor rejection as well as tumor progression, depends on the 
tumor type, stage and the types of immune cells that are involved. The data presented 
here reinforce the importance of full understanding of the intricacy of the cellular 
interactions within the tumor microenvironment. There is a rapid progress in the field 
of the cancer immunology and the development of novel cancer immunotherapy 
approaches. Therefore, tumor immunology will probably be used more commonly in 
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clinical practice in the future, as increasing evidence indicates that the effectiveness 
of several chemotherapies depends on the active contribution of the different immune 
effectors. Selecting conventional chemotherapeutic agents that induce proper immu-
nogenic tumor death can synergize with immune response modifiers to revolutionize 
cancer treatment [179]. Understanding the local and systemic immune mechanisms 
will lead to new potential therapeutic targets.
We predict that the future standard of care of lung cancer will involve patient 
tailored combination therapies that associate molecules that target specific genetic 
mutations or chemotherapeutic drugs with immune modulating agents, driven by the 
increasing understanding of the immune system in the cancer cell’s environment. The 
future for cancer treatment is bright if we are able to: I). Find a chemotherapeutic 
drug that induces immunogenic cell death in tumor cells while leaving the normal 
cells and stimulating immune cells intact. II). Explore ways to efficiently activate the 
good-natured immune system, for instance, the adoptive transfer of in vitro expanded 
activated T-cells or NK-cells, and III). Modulate the tumor environment to reduce 
local and systemic immune suppressive components while limiting potential side-
effects for the patient; e.g. by the depletion of Treg by denileukin diftitox or polarizing 
the M2 macrophage towards the M1 subtype. The treatment has to be tuned to the 
cellular make-up of each patient individually, based on their own both tumoral and 
immunological characteristics, rather than by the anatomic location of the tumor in 
the body or by the tumor histology or genetic make-up. This individualized, multi-
targeted approach will be able to redress the balance towards efficacious antitumor 
responses that can improve the overall survival for more patients.
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ABSTRACT
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of imma-
ture and progenitor myeloid cells with immunosuppressive activity that are increased 
in cancer patients. Until now, the characterization of MDSC in humans was very 
challenging. The aim of this study was to determine the characterization and optimal 
assessment of MDSC and to investigate their presence and function in blood of ad-
vanced-stage NSCLC patients. We determined MDSC and lymphocyte populations in 
peripheral blood mononuclear cells (PBMC) samples of 185 treatment-naïve NSCLC 
patients and 20 healthy controls (HC). NSCLC patients had an increased population 
of PMN-MDSC compared to HC (p<0.0001). Frequencies of CD4+ and CD8+ T-cells 
were significantly decreased in NSCLC patients (p<0.0001 and p=0.05). We found 
that PMN-MDSC were able to suppress T-cell proliferation in vitro. qRT-PCR showed 
that arginase-1 (Arg-1) mRNA is mainly expressed by MDSC and that the level of 
Arg-1 in PBMC correlates with the frequency of MDSC in PBMC (Spearman’s rho: 
0.797). There were significant differences in MDSC and lymphocyte populations 
between NSCLC patients and HC. We found that MDSC frequencies are stable up 
to six hours at room temperature after blood was drawn and that cryopreservation 
leads to a strong decrease of MDSC in PBMC. We show that Arg-1 mRNA expression 
is a valuable method to determine the levels of MDSC in peripheral blood of cancer 
patients. This method is therefore a useful alternative for the complex flowcytometric 
analysis in large multicenter patient studies.
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INTRODUCTION
The modulating effect of tumors on the immune system is challenging.1 Recent studies 
have revealed that a specific population of cells called myeloid-derived suppressor 
cells (MDSC) plays a pivotal role in tumor-associated immune suppression.2,3
MDSC are a heterogeneous population of immature myeloid cells and myeloid 
progenitor cells that can accumulate at the tumor site, in the lymphoid organs and in 
peripheral blood.4,5,6 Under pathological conditions, such as cancer, the bone mar-
row is stimulated by chemokines and cytokines like interleukin (IL)-1b, IL-6, IL-10 
and IL-6, vascular endothelial growth factor (VEGF), and colony stimulating factors 
(GM-CSF, G-CSF and M-CSF). This can lead to early release of MDSC from the bone 
marrow.7
Two major subpopulations of MDSC are defined based on the difference in expres-
sion of CD14: polymorphnuclear (PMN) MDSC and monocytic (M) MDSC. PMN-MD-
SC are characterized as CD16low,CD11b+,CD14-,HLA-DR-,CD15+,CD33+ cells, while 
M-MDSC are characterized by CD16low,CD11b+,CD14+,HLA-DR-,CD15+,CD33+.7,8,11 
In addition, PMN-MDSC and M-MDSC differ in function and quantity; M-MDSC use 
different suppressive mechanisms and are present in much smaller amounts in the 
peripheral blood of non-small cell lung cancer (NSCLC) patients than PMN-MDSC.9
There are several mechanisms by which MDSC suppress anti-tumor responses6,10-12 
and these are highly dependent on the context of their microenvironment.6,10-12 
MDSC can block anti-tumor responses by secreting cytokines, like IFN-γ, TGF-b, 
and IL-10 and by the production of reactive oxygen species (ROS), inducible NO 
synthase (iNOS), nitric oxide (NO), and arginase-1 (Arg-1).6,10-12 The presence of these 
factors suppresses features of immune responses, like T cell- and natural killer (NK) 
cell-proliferation.13 In addition, MDSC can enhance immune suppression via the 
induction of regulatory T cells (Treg).3,5,10,11
In this study we have investigated the presence, phenotypic characteristics and 
functionality of MDSC in blood of stage IV NSCLC patients. In addition, the differ-
ences between healthy controls and NSCLC patients in MDSC subpopulations and the 
other pivotal immunological subpopulations, CD4+ T cells, CD8+ T cells, and CD19+ 
B cells were determined. Furthermore, the applicability of Arg-1 mRNA expression 
as an alternative method for flowcytometry to determine the levels of MDSC in the 
PBMC fraction of these patients was analyzed.
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MATERIALS AND METHODS
Study population
All patients were participants in the NVALT12-study (trial number NCT01171170) 
a randomized phase II multicentre study on the effect of a nitroglycerin patch or 
placebo in patients with stage IV non-squamous NSCLC treated with Carboplatin 
Paclitaxel and bevacizumab. Blood samples were collected at baseline from 185 
patients who were not applicable for treatment with curative intent. The stages are in 
accordance with the American Joint Committee on Cancer (AJCC). All patients were 
treated in one of the following participating hospitals, Amphia Hospital, Breda; Dutch 
Cancer Institution, Amsterdam; VU Medical Center, Amsterdam; Haga Hospital, The 
Hague; UMCG, Groningen; UMC, Maastricht; Isala Clinics, Zwolle; Jeroen Bosch 
Hospital, Den Bosch; Martini Hospital, Groningen; Sint Antonius Hospital, Nieuwe-
gein; Deventer Hospital, Deventer; Diakonessenhuis, Utrecht; and Sint Franciscus 
Hospital, Rotterdam.
Twenty healthy controls (HC) with no history of malignancies or autoimmune 
diseases were enrolled in the study.
Written consent was obtained from all individuals before blood sampling and the 
study was approved by the ethical committee of the Erasmus Medical Center (MEC-
2012-048 (HC) and CCMO: NL33442.042.10 (NSCLC patients))
Isolation of PBMC
Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-Paque PLUS 
(GE Healthcare, Uppsala, Sweden) density gradient centrifugation. For this, blood 
was diluted 1:1 with phosphate-buffered saline (PBS, Gibco, Breda, The Netherlands) 
before layering onto the Ficoll-Paque PLUS. After centrifugating 20 minutes at 
1200xg, PBMC were collected from the plasma-Ficoll interphase. Cells were washed 
twice with PBS and counted before further analysis.
PBMC were immediately used for flowcytometric analysis or cell sorting. For quan-
titative RT-PCR, cell pellets of PBMC were snap frozen in liquid nitrogen and stored 
at -800C until RNA isolation.
For the experiments where the influence of freezing was tested, part of the PBMC 
was frozen using RPMI 1640 (Gibco), 40% fetal calf serum (FCS, Sigma Aldrich Che-
mie GmbH, Steinheim, Germany), 10% dimethyl sulphoxide (DMSO, Sigma Aldrich) 
and stored at -1500C until use.
Flowcytometry and cell sorting
PBMC were stained with anti-CD15 FITC or PE, anti-CD16 PE or PERCP-Cy5.5, 
anti-CD124 PE, anti-CD66b PE, anti-CD33 PE Cy7, anti-CD11b APC, anti-HLA-DR 
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APC-Cy7 (all BD Biosciences), anti-CD14 PE-Texas-Red (Invitrogen, Breda, The Neth-
erlands), and a live/dead marker 4’,6-diamidino-2-phenylindole (DAPI, Molecular 
Probes, Eugene, OR, USA) to analyze MDSC. Staining with anti-CD4 FITC, anti-CD8 
APC, anti-CD19 PERCP-Cy5.5 (all BD Biosciences), anti-CD3 APC-eFluor 780 (eBio-
science, San Diego, CA, USA), and DAPI was performed for the analysis of T- and B 
cells.
Cells were washed with FACS buffer (PBS, 0.25% BSA, 5 mM EDTA, 0.05% NaN3) 
and stained for 30 min at 40C with the above mentioned antibodies, appropriately 
diluted in FACS buffer supplemented with 2% normal human serum.
Acquisition of 5 to 8 color samples was done on a LSRII flowcytometer (BD Biosci-
ences). Cell sorting was performed on a FACS Aria (BD Biosciences). Analysis of the 
data was done using FlowJo software (Treestar, San Carlos, CA, USA).
Detection of reactive oxygen species (ROS)
The oxidation sensitive molecule 2’,7’-dichlorofluorescein diacetate (DCFDA, Sigma) 
was used to measure ROS production by MDSC. Cells were incubated at 370C in 
RPMI 1640 in the presence of 0.5 mM DCFDA for 10 minutes and washed twice with 
cold FACS buffer. Cells were subsequently stained for flowcytometry as described 
above.
Real-time quantitative RT-PCR
Frozen cell pellets were homogenized and RNA was isolated using RNAqueous 
micro kit (Ambion Inc, Austin, TX, USA) for sorted cell populations or RNeasy mini 
kit (Qiagen, GmbH, Hilden, Germany) for PBMC, followed by DNAse I treatment. 
RNA (100 ng) was reverse transcribed using RevertAid H minus First Strand cDNA 
Synthesis Kit (Fermentas GmbH, St. Leon-Rot, Germany) with random hexamer prim-
ers according to the manufacturers’ protocol.
Quantitative RT-PCR for Arg-1 was performed using maxima SYBR Green qPCR 
mastermix (Fermentas). The following primers were used: b-Actine, forward: CTGTG-
GCATCCACGAAACTA, reverse: AGTACTTGCGCTCAGGAGGA; and for Arginase-1, 
forward: GTTTCTCAAGCAGACCAGCC, reverse: GCTCAAGTGCAGCAAAGAGA.14 
PCR conditions were 2 min at 500C, 10 min at 950C, followed by 40 cycles of 15 s at 
950C and 600C for 1 min using an ABI PRISM 7300 (Applied Biosystems, Carlsbad, 
CA, USA). PCR amplification of the house keeping gene b-actin was performed dur-
ing each run for each sample to allow normalization between samples.
T cell suppression assay
PBMC were isolated from a buffy coat of a healthy donor (Sanquin, Amsterdam, 
The Netherlands) using Ficoll gradient centrifugation as described above. CD8+ T 
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cells were isolated using a CD8 T cell isolation kit (Miltenyi Biotec B.V., Leiden, The 
Netherlands) according to manufacturers’ protocol. For labeling with carboxyfluores-
cein succinimidyl ester (CFSE, Molecular Probes), CD8+ T cells were washed twice 
with serum-free RPMI 1640 and subsequently labeled with 5 µM CFSE in serum-free 
medium for 10 min at 370C. The reaction was stopped by adding an excess of ice-cold 
RPMI 1640 supplemented with 10% FCS.
CFSE labeled CD8+ T cells were stimulated using anti-CD3/anti-CD28 beads (Invi-
trogen) and co-cultured in a 5:1 ratio with FACS sorted PMN-MDSC in RPMI 1640 
supplemented with 20% of pleural effusion of a cancerous patient to prevent further 
differentiation of MDSC. At day 4, cells were harvested and stained for flowcytometry 
using anti-CD3 APC-eFluor780 (eBioscience), and anti-CD8 APC (BD Biosciences). 
Cell division was quantified based on serial halving of CFSE intensity, algorithms 
provided by FlowJo software (Treestar) were used. Data are shown as percentage of T 
cells recruited into cell division, calculated as previously described.15
Statistical analysis
Differences between healthy controls and NSCLC patients were analyzed by using 
the Mann–Whitney U test. Correlations were assessed by using the Spearman’s rho 
correlation test. Statistical analysis was performed using the statistical program SPSS 
(version 17.0, SPSS Inc, Chicago, USA). All p-values were two-sided and p-values 
below the conventional level of significance (p<0.05) were considered statistically 
significant. Figures were made in GraphPad Prism (version 7.0, GraphPad Software, 
San Diego, CA, USA).
RESULTS
Characteristics of study subjects
Table 1 shows the characteristics of the 185 study participants and 20 healthy con-
trols. An approximately equal distribution in gender was seen in the NSCLC group, 
while most of the healthy controls were female (80%). The mean age in the NSCLC 
group was 60 years and in the control group 54 years. Adenocarcinoma was the most 
common histological type (85.4%), followed by large cell carcinoma (14.1%) and 
adenocarcinoma in situ (0.5%). Most NSCLC patients had a WHO performance score 
of 0 (47.0%) or 1 (49.3%) at time of inclusion in this study. All healthy controls had a 
WHO performance score of 0.
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Phenotypical characterization of MDSC subsets
MDSC populations in peripheral blood were characterized using flowcytometric 
analysis after density gradient centrifugation. A broad panel of markers was used to 
detect MDSC, including CD14, CD15, CD16, CD33, CD11b, HLA-DR, and DAPI 
as a live/dead marker, because unique markers are not identified yet.6 Two MDSC 
subsets were identified in blood: PMN-MDSC and M-MDSC.11 The gating strategy is 
Table 1: Subject characteristics of 20 healthy controls and 185 NSCLC patients.
Healthy controls NSCLC patients
Number of subjects 20 185
Age (years) (Mean ± SD) 54 ± 7.5 60 ± 8.5
Gender (%)
 Male 4 (20) 93 (50.3)
 Female 16 (80) 92 (49.7)
WHO performance score (%)
 0 20 (100) 87 (47.0)
 1 91 (49.2)
 2 7 (3.8)
Histologic subtype (%)
 Adenocarcinoma 158 (85.4)
 Large cell carcinoma 26 (14.1)
 Brochoalvoolar carcinoma 1 (0.5)
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Figure 1: Gating strategy used for the identification of PMN- and M-MDSC. PBMC were isolated 
from peripheral blood by density gradient centrifugation and subsequently stained for flowcytometric 
analysis. After excluding debris and death cells, the CD16 low cells were selected. Then CD11b+ 
CD14+ or CD11b+ CD14- cells were gated, followed by selecting the HLA-DR negative population. 
The final gate is CD33+ CD15+ cells, markers expressed on both PMN-MDSC and M-MDSC 
populations.
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shown in figure 1. Initial experiments showed a distinct population of PMN-MDSC 
(mean: 0.95% of alive) in contrast to M-MDSC which were hardly detectable in blood 
of stage IV NSCLC patients (mean: 0.009% of alive).
CD124 (IL-4Rα) on MDSC, as described in several studies16,17, was detectable at 
a very low level on PMN-MDSC. However the same expression was seen on other 
myeloid cells (data not shown) so this marker has no additional value to discriminate 
between PMN-MDSC and other PBMC.
Functional characterization of PMN-MDSC
PMN-MDSC express diverse factors that contribute to their immune suppressive ac-
tivity, including ROS and Arg-1, which can suppress T cell function.3 ROS production 
by PMN-MDSC was measured by flowcytometry. The high fluorescent DCF signal 
demonstrated that a high amount of ROS was present within PMN-MDSC (figure 2a) 
compared to the negative control.
To evaluate the production of Arg-1 by PMN-MDSC, the mRNA level was measured 
by qRT-PCR. Figure 2b shows that Arg-1 is mainly produced by PMN-MDSC. This 
confirms that high Arg-1 mRNA expression is characteristic for PMN-MDSC (figure 
2b).
To assess the suppressive capacity of MDSC16,20, sorted PMN-MDSC were co-
cultured with CFSE labeled CD8+ T cells. In the absence of PMN-MDSC 55% of the 
CD8+ T cells were recruited into cell division. This percentage decreased to 5.8% 
when PMN-MDSC were added to the culture (figure 2c). This demonstrates that the 
sorted PMN-MDSC strongly inhibit T cell proliferation in vitro.
Effect of cryopreservation on the recovery of PMN-MDSC
In our study, PBMC from NSCLC patients from several hospitals in the Netherlands 
were analyzed. Therefore, the recovery of the PMN-MDSC after cryopreservating 
PBMC was analyzed to test whether the blood could be cryopreserved before analysis.
PBMC were divided into two portions; one was immediately used for FACS analysis, 
while the other was frozen in 10% DMSO and stored at -1500C. As shown in figure 
3a and 3b, the percentage of PMN-MDSC was strongly reduced in the frozen/thawed 
samples (n = 10). Only 11% of the cells was recovered after cryopreservation (figure 
3a and 3b).
Overnight storage of blood for PMN-MDSC analysis at 4°C
After our finding that frequencies of PMN-MDSC dramatically decrease after cryo-
preservation, the question raised whether it is possible to store the blood overnight 
(o/n) at 40C or at room temperature (RT) without influencing the frequency of PMN-
MDSC. 
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Figure 2: Functional characterization of PMN-MDSC 2A) Expression of ROS by PMN-MDSC. PBMC 
were incubated with DCFDA, which is converted into fluorescent DCF in the presence of ROS. The 
ROS expression in PMN-MDSC is compared to PMN-MDSC not exposed to DCFDA. 2B) mRNA 
levels of Arg-1. PMN-MDSC, monocytes and CD14-CD11b+ cells were sorted from 4 patients and 
used for RNA isolation. The Arg-1 level is 1000x lower in monocytes and 22x lower in CD11b-CD14- 
cells compared to PMN-MDSC. 2C) PMN-MDSC were sorted from PBMC and tested for their ability 
to suppress T cell proliferation. PMN-MDSC and CFSE-labelled T cells were co-cultured in a 1:5 
ratio and stimulated with anti-CD3/anti-CD28 beads. After 4 days T cell proliferation was measured. 
Percentages indicated in the plots represent the percentage of cells recruited into cell division. 
Representative results from one out of three experiments are shown.
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Figure 3: Frequency of PMN-MDSC in directly isolated PMBC compared to the frequency in 
cryopreserved or overnight stored blood samples (n=10). 3A) Fold change in frequency of PMN-
MDSC after cryopreservation and o/n storage at 40C or RT. 3B) Changes in frequency of PMN-MDSC 
after cryopreservation, o/n 40C or RT per patient. 3C) PBMC were isolated from peripheral blood 
directly after blood was drawn or after storage for 2, 4, 6, and 24 hours at RT (n = 4). No significant 
differences were seen in PMN-MDSC frequencies until 6 hours after the blood was drawn. However, 
after 24 hours of storage, the number of PMN-MDSC was significantly decreased (p = 0.0073).
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For this experiment, three blood tubes of 10 ml were obtained per patient (n = 
10). One tube was used for analysis within two hours after the blood was drawn, the 
other two were stored o/n at 40C or at RT. PBMC isolation and FACS analysis were 
performed the next day. 
As shown in figure 3a and b, the percentage of PMN-MDSC is 2.7 fold higher when 
blood is stored o/n at 40C, compared to the freshly analyzed samples. Also the total 
amount of PBMC per ml blood is increased, which can be caused by a difference in 
cell density. Storage of blood at 40C can result in an overestimation of the percentage 
of PMN-MDSC. Overnight storage at RT leads to a 1.6 fold decrease in PMN-MDSC 
percentage (figure 3a and 3b).
Short-term storage of blood for PMN-MDSC analysis
To determine if variations in PMN-MDSC percentage are introduced over time, due to 
differences in processing time caused by transportation, we studied the influence of 
short-term storage on the recovery of PMN-MDSC. Blood samples of NSCLC patients 
samples were analyzed immediately or after 2, 4, 6, and 24 hours after the blood was 
drawn. Figure 3c shows that the percentage of PMN-MDSC remains constant at room 
temperature in the first six hours. A reduction of 50% was found when the blood is stored 
overnight.
After our finding that frequencies of PMN-MDSC dramatically decrease after cryo-
preservation, the question raised whether it is possible to store the blood overnight (o/n) 
at 40C or at room temperature (RT) without influencing the frequency of PMN-MDSC. 
For this experiment, three blood tubes of 10 ml were obtained per patient (n = 
10). One tube was used for analysis within two hours after the blood was drawn, the 
other two were stored o/n at 40C or at RT. PBMC isolation and FACS analysis were 
performed the next day. 
As shown in figure 3a and b, the percentage of PMN-MDSC is 2.7 fold higher when 
blood is stored o/n at 40C, compared to the freshly analyzed samples. Also the total 
amount of PBMC per ml blood is increased, which can be caused by a difference in 
cell density. Storage of blood at 40C can result in an overestimation of the percentage 
of PMN-MDSC. Overnight storage at RT leads to a 1.6 fold decrease in PMN-MDSC 
percentage (figure 3a and 3b).
Frequencies of PMN-MDSC and M-MDSC are increased in PBMC of NSCLC 
patients
Using gradient density centrifugation and flow cytometry, the frequency of PMN-
MDSC and M-MDSC was analyzed in the PBMCs of 185 NSCLC patients and 
20 healthy controls. Table 2 and figure 4a show the percentages, expressed as 
% of alive cells, and absolute numbers, expressed as cells/mL blood of circulat-
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Figure 4: Frequency of PMN-MDSC, CD4+, CD8+ T cells and CD19+ B cells in healthy controls 
(HC) and NSCLC patients (LC pt). 4A) Data showing the difference between HC and LC pt in the 
percentage of alive of PMN-MDSC (left) and the absolute number per ml of PMN-MDSC (right) in the 
peripheral blood. Data are presented as box-and-whisker plots (1-99 percentile) showing the median, 
quartiles and outliers. 4B) The difference between HC and LC in percentage of alive (left) and absolute 
number per ml (right) of M-MDSC. 4C) The percentage of alive (left) and absolute numbers per ml 
blood (right) of CD4+ T cells, 4D) CD8+ T cells and 4E) CD19+ B cells.
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ing PMN-MDSC (CD16low,CD11b+,CD14-,HLA-DR-,CD15+,CD33+) and M-MDSC 
(CD16low,CD11b+,CD14+,HLA-DR-,CD15+,CD33+). Analysis of circulating PMN-MDSC 
revealed that there was a significantly higher percentage, 1.212 vs 0.064 (p < 0.001), 
and absolute number (p < 0.001) of PMN-MDSC in the peripheral blood of NSCLC 
patients compared to healthy controls (figure 4b). Also the absolute number and per-
centage of M-MDSC was significantly higher (p =0.036 and p = 0.002) in patients.
Frequency of T cells is decreased in PBMC of NSCLC patients
To further investigate differences in PBMC between patients and healthy controls per-
centages and absolute numbers of circulating CD4+ T cells, CD8+ T cells and CD19+ 
B cells, were measured (table 2). CD4+ T cells and CD8+ T cells in the peripheral 
blood of NSCLC patients were significantly decreased compared to healthy controls 
(p < 0.0001 and p = 0.05, respectively of frequency of alive)(figure 4c/d). Also the 
absolute numbers of CD4+ T cells and CD8+ T cells were significantly decreased (p < 
0.001 and p = 0.018, respectively). The frequency of alive and the absolute numbers 
of CD19+ B cells were similar between healthy controls and patients (figure 4e).
Arginase-1 mRNA expression correlates with frequency of PMN-MDSC
Arg-1 activity is one of the suppression mechanisms of MDSC. To investigate the 
differences in Arg-1 mRNA expression in HC and NSCLC patients, the Arg-1 mRNA 
expression was measured in both groups using a qRT-PCR. As shown in figure 5a, 
the expression in NSCLC was significantly higher compared to the HC (p < 0.0001).
As shown in our results above, Arg-1 mRNA is mainly expressed by PMN-MDSC in 
peripheral blood. To confirm this, Arg-1 mRNA levels in PBMC were correlated with 
the frequency of PMN-MDSC in the peripheral blood of NSCLC patients. A significant 
correlation between these two measures was seen (Spearman’s rho: 0.797, p-value 
< 0.0001).
Table 2: Differences in MDSC populations, T cells and B cells between healthy controls (HC) and 
NSCLC patients. The table shows the mean percentage of alive of five pivotal immunological cell 
types in HC and NSCLC patients. The p-values were assessed by using a Mann–Whitney U test.
Cell type (mean percentage of 
alive) Healthy controls NSCLC patients p-value
MO-MDSC (± SD) 0.006 (± 0.02) 0.150 (± 1.19)  0.002
PMN-MDSC (± SD) 0.064 (± 0.05) 1.212 (± 2.97)  < 0.0001
CD4+ T cell (± SD) 39.1 (± 7.33) 24.3 (± 11.87) < 0.0001
CD8+ T cell (± SD) 15.1 (± 5.61) 12.6 (± 7.36) 0.050
CD19+ B cell (± SD) 6.9 (± 2.12) 7.9 (± 6.13) 0.575
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DISCUSSION
It has been described that MDSC are present in most cancer patients.6 To our knowl-
edge, this is the first large study with 185 patients that demonstrates that MDSC 
are present in Caucasian NSCLC patients. Earlier, MDSC have been reported in a 
relatively small (n = 10) heterogeneous population of lung cancer patients23 and in 
two other studies that investigated MDSC in a genetically different population of 
Asian lung cancer patients.9,24 Both studies used a limited set of markers to define the 
MDSC population. This phenotypic diversity of MDSC, as well as the lack of common 
markers to study these cells, has generated ambiguity in their characterization. Con-
sequently, the described suppressive activity of the MDSC can be due to the influence 
of other cells, for instance, suppressive CD16+ granulocytes. In this study an extensive 
set of all known markers for MDSC was included to characterize these cells.
In the present study, we demonstrate a significant increase in circulating MDSC in 
patients compared to healthy controls, while, on the contrary, the populations of CD4+ 
T cells and CD8+ T cells were decreased. Furthermore, there is a high expression of 
Arg-1 mRNA which correlated with the percentage of PMN-MDSC and suppression 
assays showed that PMN-MDSC have the ability to suppress CD8+ T cell activity. No 
differences in mRNA expression between males and females (data not shown) were 
seen. Therefore, selection bias is not likely.
As there was no clear consensus whether PBMC cryopreservation influences the 
phenotype, frequency and functionality of MDSC, PMN-MDSC were compared 
before and after cryopreservation, as cryoperservation is useful for large multicenter 
studies and reduces the day-to-day variability. Our data indicate that cryopreservation 
of PBMC had a strong impact on the PMN-MDSC recovery and led to a significant 
reduction in their frequency (figure 3a).22 Therefore, when PMN-MDSC are studied in 
human blood samples it is essential to use fresh, not cryopreserved cells. In addition, 
it is recommended to analyze the blood within 6 hours.
Figure 5: Arginase-1 (Arg-1) mRNA expression is increased in the peripheral blood of NSCLC patients 
(LC pt) Figure 5 shows the difference in mRNA expression of Arginase-1 in PBMC between healthy 
controls (HC) and LC pt (p < 0.0001).
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In this study we have also shown that the numbers of CD4+ and CD8+ T cells 
were significantly decreased in NSCLC patients compared with healthy controls. It 
has been described that in cancer patients the decreased number of lymphocytes is 
(partially) due to the suppressive effects of MDSC and Treg on T cells.28 In addition, 
lower thymic output and a higher apoptosis rate can cause lower frequencies of 
lymphocytes.29 Decreased numbers of lymphocytes in peripheral blood are associ-
ated with worse survival of lung cancer.24,27 As described in literature, no differences 
in B cell numbers were found.41
There are multiple immunosuppressive mechanisms that can be used by 
MDSC.3,6,10,11 L-arginine depletion by enzymatic activity of Arg-1 is probably one 
of the most important pathways to be reported in human MDSC.12,17,30 In the cur-
rent study we showed Arg-1 is mainly produced by PMN-MDSC and the percentage 
of PMN-MDSC correlates with the Arg-1 levels in the peripheral blood of NSCLC 
patients (figure 5). In addition, we suggest that Arg-1 could be used as a surrogate 
marker for the frequency of MDSC in PBMC. This could have major advantages; first, 
Arg-1 expression levels can be measured by qRT-PCR instead of six non-specific 
markers that are needed to identify the MDSC population with flowcytometry. As a 
result, no expensive flowcytometers are needed to investigate this cell population. 
Next to this, Arg-1 can be reliably measured in the PBMC fraction that is snap frozen 
after ficoll isolation. This is useful for large patient multicenter studies, because Arg-1 
can be measured at a later time point, in contrast to measuring MDSC on FACS. This 
might be a valuable tool to reduce the day-to-day variability.
The main effects of Arg-1 expression on T-cell dysfunction are caused by L-arginine 
depletion.3,32 It has been described that T cells cultured in medium lacking L-arginine 
showed a decrease of CD3zeta expression, an activation marker for T-cells. The loss 
of CD3zeta expression fully reestablished after replacement of L-arginine and citrul-
line.31,33,34 The other mechanism by which Arg-1 can cause T cell dysfunction is L-
arginine deprivation that can specifically inhibit the cell cycle progression leading to 
decreased T-cell proliferation.3,35 The addition of L-arginine to the L-arginine deprived 
cells without L-arginine recovered the cell cycle progression.35
In the future, lung cancer treatment might be tailored to the cellular make-up of 
each patient individually, based on tumoral and immunological characteristics.36,37A 
strategy could be to intervene with the immunosuppressive pathways used by 
MDSC.3,28 In case of the Arg-1 immunosuppressive mechanism, the addition of ar-
ginase inhibitors N-Hydroxy-nor-L-Arg (Nor-NOHA) and N-Hydroxy-L-Arg (NOHA) 
or exogenous L-arginine partially prevented the reduction of L-arginine in culture 
and reversed the loss of CD3zeta on T-cells.31,32,38 The same was seen in vivo in Lewis 
lung carcinoma bearing mice; inhibition of Arg-1 decreased the tumour growth.39 We 
found high mRNA levels of Arg-1 in NSCLC patients compared to healthy controls; 
114 Chapter 8
Therefore, Arg-1 inhibitors may represent a target for new therapies in lung cancer 
patients.
In conclusion, there are significant differences in MDSC and lymphocyte popula-
tions between NSCLC patients and healthy controls. We found that Arg-1 mRNA is 
mainly expressed in PMN-MDSC and correlates with the frequency of PMN-MDSC in 
the PBMC fraction of peripheral blood. Therefore, we propose that qRT-PCR on Arg-1 
might be useful as an additional or alternative method for flowcytometry to determine 
the levels of PMN-MDSC in peripheral blood of cancer patients.
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ABSTRACT
Introduction It is well known that pulmonary tuberculosis is associated with an 
increased risk of lung cancer. We investigated whether a history of pulmonary tuber-
culosis is an independent risk factor for lung cancer survival in Caucasian patients.
Methods The data of the prospective population-based cohort of The Rotterdam Study 
were used. During a mean follow-up time of 18 years, there were 214 incident cases 
of pathology-proven lung cancer in a source population of 7983 study participants. 
History of tuberculosis was assessed at baseline by interviewers using standardized 
questionnaires. Associations of lung cancer survival with the occurrence of pulmo-
nary tuberculosis were assessed using Cox’s proportional hazard regression analysis 
adjusted for age, gender, pack-years, educational level and tumor stage.
Results A history of tuberculosis was reported in 13 of the 214 subjects with lung 
cancer. The survival of patients with lung cancer was significantly shorter in subjects 
with a history of pulmonary tuberculosis (HR = 2.36, CI95%: 1.1-4.9), than in sub-
jects without a history of pulmonary tuberculosis with a mean difference of 311 days.
Conclusion: The presence of a history of pulmonary tuberculosis may be an important 
prognostic factor in the survival of lung cancer.
KEY WORDS
Lung cancer, tuberculosis, prognostic factor, survival
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INTRODUCTION
Worldwide, lung cancer is the most common cause of cancer mortality with a 
five-year survival rate of only 15%.1 Recently, it has been described that a strong 
increase in the incidence rate of lung cancer is expected in developing countries.2 
The incidence of tuberculosis is over 9 million new cases per year worldwide, with an 
uneven distribution. Developing countries harbor a large burden of tuberculosis. In 
South Africa, for example, there was a six-fold increase of tuberculosis cases over the 
past two decades.3 Given the large numbers of morbidity and mortality worldwide 
of both lung cancer and tuberculosis, associations between these epidemics deserve 
investigation. It is well known that pulmonary tuberculosis is associated with an 
increased risk of lung cancer.4-6
Although it is not completely understood what the underlying mechanism for this 
increased risk is, it has been reported that scarring of the lung after tuberculosis 
predisposes to the development of lung cancer in these patients, especially adeno-
carcinoma.4-6 Recent data suggest that ongoing inflammatory reactions in the lungs 
of these patients are the primary cause of scar formation and may be the cause of 
malignant transformation of cells in these areas.4-6
Apart from the fact that tuberculosis scar formation has been identified as a risk 
factor for lung cancer development, there is evidence that a history of tuberculosis 
might be an additional prognostic factor for lung cancer survival5,7, next to other 
well-known prognostic factors such as disease stage and World Health Organization 
(WHO) performance status.8 It has been reported that patients with active pulmo-
nary tuberculosis at the time of lung cancer diagnosis or pulmonary tuberculosis 
development within 2-10 years before or after the diagnosis of lung cancer have a 
shorter survival time than those without pulmonary tuberculosis in the same periods.5, 
7 However, these retrospective studies had a number of methodological limitations, 
notably selection- as well as information bias. So far, no population-based prospec-
tive cohort studies have been performed to investigate whether there is a difference in 
mortality of lung cancer in patients with and without a life long history of pulmonary 
tuberculosis.
Therefore, the objective of our study was to investigate whether a history of 
pulmonary tuberculosis is an independent risk factor for lung cancer survival in a 
prospective population-based cohort study of Caucasian patients in the Netherlands.
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MATERIAL AND METHODS
Source population
Data were obtained from The Rotterdam Study9, a population-based prospective 
cohort study in Rotterdam, the Netherlands. The main objective of The Rotterdam 
Study is to investigate chronic diseases and their risk factors in an elderly population. 
All inhabitants of the Rotterdam suburb Ommoord aged ≥ 55 years were invited to 
participate in the study, which started with a baseline interview between July 1989 
and July 1993. Of the 10,215 eligible subjects, 7,983 (78%) agreed to participate.9 
The Medical Ethics Committee of the Erasmus Medical Center approved the study and 
all participants gave written informed consent. Participants were visited at home at 
the start of the study for a standardized interview on health state and socio-economic 
characteristics. Afterwards, an extensive physical examination and blood assessment 
followed at the research center. Since the start of the study, cross-sectional surveys 
have been carried out periodically. In addition, participants are continuously moni-
tored for major events, including cancer, which occurred during follow-up, through 
automated linkage with files from general practitioners, and laboratories. Information 
on their vital status is obtained regularly from public health authorities and general 
practitioners in Rotterdam.
Study population
From January 1st, 1990 to December 31st 2008, 214 pathologically confirmed incident 
lung cancer cases were diagnosed in our cohort. The diagnoses of lung cancer were 
obtained through information from the general practitioners and by linkage with a 
nationwide pathology registry (PALGA). Two research physicians independently vali-
dated lung cancer cases on the basis of medical records of the general practitioner, 
discharge letters, and pathology reports and assessed the first date and diagnosis of 
lung cancer. All events were classified according to the International Classification of 
Disease (ICD) tenth edition.10 The start date of a participant in this study was defined 
as the date of first diagnosis of lung cancer. Patients were followed until death, or 
end of the study period (December 31st, 2008), whichever came first. Causes of death 
were defined using information obtained from the death certificate or from the clinics.
Information on tobacco use was collected during the home interview. Smoking 
status was repeatedly assessed during follow-up every 3- to 4-years. So, people were 
classified as current smokers, past smokers and never smokers on a continuous basis. 
Moreover, the number of pack-years was calculated.
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Exposure definition
Pulmonary tuberculosis was assessed by standardized home-interviews at baseline 
by the questions: “Did you ever experience tuberculosis?”, “Did you have a course of 
treatment for tuberculosis?”, “Was your tuberculosis treated with drugs?” and “What 
was your age at the time of first diagnosis of tuberculosis?”
Statistical analysis
The patient survival time for lung cancer was calculated as the period between the 
first date of the pathologically confirmed diagnosis of lung cancer and death, or end 
of the study period. Associations between pulmonary tuberculosis and lung cancer 
survival were assessed by using Cox’s proportional hazard regression analysis and 
expressed as hazard ratios with 95% confidence limits (95%CI). The results were 
adjusted for age, gender, pack-years of smoking, smoking status, level of education, 
histology of the tumor and tumor stage, because these factors have been described 
to influence the lung cancer survival and were considered as potential confounders. 
Information about smoking status was repeatedly updated every 3- to 4 years. Statisti-
cal analysis was performed using the statistical program SPSS (version 15.0, SPSS Inc, 
Chicago, USA). All p-values were two-sided and p-values below the conventional 
level of significance (p<0.05) were considered statistically significant.
RESULTS
Table 1 shows the characteristics of the 214 study participants of whom 13 had a 
history of tuberculosis. All patients had developed their tuberculosis before the di-
agnosis of lung cancer. Approximately two third of the 214 subjects participating in 
this study were male (p = 0.113). The mean age at diagnosis of lung cancer was 77 
years (p = 0.094). Most subjects currently smoked tobacco or had a history of smok-
ing (86.4%) with a mean of 36.8 pack-years (p = 0.293). In the tuberculosis group, 
large cell carcinoma was the most common histological type (38.5%), followed by 
adenocarcinoma (30.8%) and small cell lung carcinoma (SCLC) (7.7%), as shown 
in table 1. In the non-tuberculosis group, large cell carcinoma was the most com-
mon histological type (28.4%), followed by squamous cell carcinoma (23.9%), SCLC 
(14.4%) and adenocarcinoma (12.4%) (p = 0.521). 30.8% of the tuberculosis cases 
had at least intermediate vocational education against 38.4 % of the non-tuberculosis 
group (p = 0.278).
Table 2 shows the crude and the adjusted hazard ratios (HR) for time to death 
within lung cancer patients. The hazard ratios (HR) divide the death rate in lung can-
cer patient with the characteristic by the death rate in lung cancer patients without 
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Table 1 shows the subject characteristics of 214 lung cancer patients with and without a history of 
tuberculosis.
Characteristic
Number  
(% of total)
History of tuberculosis 
number (%)
No history of 
tuberculosis (%) p-value
   
Number of subjects 214 (100) 13 (6.1) 201 (93.9)  
Follow-up (days) (Mean 
± SD) 473 ± 733 182 ± 180 493 ± 751 <0.001
Age at diagnosis (years) 
(Mean ± SD) 77 ± 9.1 73 ± 8,3 77 ± 9.1 0.094
Gender   
 Male 144 (67.3) 11 (84,6) 133 (66.2) 0.113
 Female 70 (32.7) 2 (15.4) 68 (33.8)  
Smoking Status   
 Never 20 (9.3) 0 (0) 20 (10.0) 0.003
 Current 119 (55.6) 9 (69.2) 110 (54.7)  
 Former 66 (30.8) 4 (30.8) 62 (30.8)  
 Unknown 9 (4.3) 0 (0) 9 (4.5)  
Pack-years (Mean ± SD) 36.8 ± 27.8 48.7 ± 26,3 36 ± 27.8 0.293
Stage of lung cancer at 
diagnosis   
 I 4 (1.9) 0 (0) 4 (2.0) 0.626
 II 13 (6.1) 1 (7.7) 12 (6.0)  
 III 34 (15.9) 3 (23.1) 31 (15.4)  
 IV 139 (65.0) 8 (61.5) 131 (65.2)  
 Unknown 24 (11.2) 1 (7.7) 23 (11.4)  
Histologic subtype   
 Squamous cell 48 (22.4) 0 (0) 48 (23.9) 0.521
 Adenocarcinoma 29 (13.6) 4 (30.8) 25 (12.4)  
 Large cell 62 (29.0) 5 (38.5) 57 (28.4)  
 SCLC 30 (14.0) 1 (7.7) 29 (14.4)  
 Unknown 45 (21) 3 (23.1) 42 (20.9)  
Highest education   
 Primary 76 (35.5) 6 (46.2) 70 (34.8) 0.278
 Lower vocational 33 (15.4) 2 (15.4) 31 (15.4)  
 Lower secondary 20 (9.3) 1 (7.7) 19 (9.5)  
 Intermediate 
vocational 59 (27.6) 4 (30.8) 55 (27.4)  
 General secondary 12 (5.6) 0 (0) 12 (6.0)  
 Higher vocational 10 (4.7) 0 (0) 10 (5.0)  
 Unknown 4 (1.9) 0 (0) 4 (2.0)  
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Table 2 shows the crude and the adjusted hazard ratios (HR) for time to death within lung cancer 
patients. The hazard ratios (HR) divide the death rate in lung cancer patient with the characteristic 
by the death rate in lung cancer patients without the characteristic (reference group) as a measure of 
relative risk.
Characteristic* Crude HR Adjusted HR
 (95%CI) (95%CI)
History of tuberculosis 1.75 (1.0-3.1) 2.36 (1.13-4.91)
Age at diagnosis (years) 1.00 (0.99-1.01) 0.98 (0.96-1.01)
Gender   
 Male 1.08 (0.8-1.5) 1.09 (0.70-1.71)
 Female 1.00 (reference) 1.00 (reference) 
Smoking Status   
 Never 1.00 (reference) 1.00 (reference)
 Current 0.82 (0.5-1.3) 0.85 (0.5-1.4)
 Former 1.46 (0.7-2.9) 1.52 (0.8-3.0)
Pack-years
 0 1.00 (reference) 1.00 (reference)
 1-10 1.76 (0.2-13.6) 2.27 (0.26-19.98)
 11-20 2.10 (0.3-16.3) 3.74 (0.43-32.75)
 >20 1.44 (0.2-10.4) 2.38 (0.28-20.03)
Stage of lung cancer at diagnosis   
 I 1.00 (reference) 1.00 (reference) 
 II 1.31 (0.4-4.7) 1.47 (0.35-6.24)
 III 3.81 (1.0-14.6) 2.68 (0.60-11.96)
 IV 4.83 (1.5-15.3) 4.73 (1.22-13.92)
Histologic subtype   
 SCLC 1.00 (reference) 1.00 (reference)
 Squamous cell 2.13 (1.42-3.21) 2.71 (1.54-4.77)
 Adenocarcinoma 2.70 (1.65-4.42) 1.94 (0.91-4.18)
 Large cell 1.27 (0.77-2.08) 3.00 (1.54-5.86)
Highest education   
 Primary 1.00 (reference) 1.00 (reference)
 Lower vocational 0.69 (0.25-1.97) 0.16 (0.05-0.48)
 Lower secondary 1.20 (0.42-3.40) 0.22 (0.07-0.70)
 Intermediate vocational 0.89 (0.31-2.52) 0.22 (0.07-0.70)
 General secondary 1.36 (0.46-4.00) 1.40 (0.45-4.37)
 Higher vocational 0.72 (0.26-2.01) 0.24 (0.08-0.66)
* See table 1 for absolute numbers.
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the characteristic (reference group) as a measure of relative risk. The crude HR of 
history of tuberculosis shows a 1.75-fold increased risk (95%CI: 1.0-3.1) and the HR 
of history of tuberculosis adjusted for age, gender, disease stage, histological subtype, 
highest education, smoking status and pack-years, shows a 2.36-fold increased risk 
(95%CI: 1.1-4.9) with a mean difference of 311 days.
Figure 1 shows the differences in survival of lung cancer in patients with a history 
of tuberculosis and patients without a history of tuberculosis. The survival time is 
defined as the time period between date of first diagnosis of lung cancer and death 
due to lung cancer, or end of the study period (December 31st, 2008), whichever 
came first. The total number of deaths due to lung cancer was 208 out of 214. Six 
patients without a history of tuberculosis were still alive at the end of the study period 
whereas those with a history of tuberculosis had all died.
DISCUSSION
To our knowledge, this is the first study that demonstrates that a history of pulmonary 
tuberculosis is an independent poor prognostic risk factor for lung cancer survival. 
Earlier, it has been reported that patients with active pulmonary tuberculosis at the 
time of lung cancer diagnosis or pulmonary tuberculosis up to more than 10 years 
Figure 1 Survival function from diagnosis of lung cancer. The figure shows the differences in 
cumulative survival in patients with and without a history of tuberculosis. The x-axis is the follow-
up time (fup) in days, which is defined as the time period between the date of first diagnosis of lung 
cancer and death, or end of the study period (December 31st, 2008), whichever came first.
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before the diagnosis of lung cancer have a shorter survival time than those without 
pulmonary tuberculosis.5, 7 The first study was a case-control study performed fifteen 
years ago in Taiwan.5 A limitation of this study is that patients were described only 
if they were diagnosed with tuberculosis up to 2 years before they were diagnosed 
with lung cancer, or patients who were diagnosed with lung cancer and tuberculosis 
at the same time. This might have introduced selection bias as well as information 
bias. Another limitation of that study is that the survival analysis was confounded 
by a pivotal prognostic factor of lung cancer, i.e. stage of disease. The second study 
was a cohort study performed among farmers living in the rural county of Xuanwei, 
China.7 These farmers had the highest lung cancer mortality rates among the country; 
therefore, in our opinion, these results indicate a lack of external validity.4-7, 11
It is well known that there are two major prognostic factors for lung cancer: WHO 
performance status and disease stage, but there are also differences in survival of lung 
cancer between the different histological subtypes.10-13 The distribution of histological 
subtype in the group of patients without a history of tuberculosis is similar to what is 
found in the general population in the Netherlands.14 An epidemiological study in a 
large group of tuberculosis patients already demonstrated that the relative risk for lung 
cancer subtypes in patients with a history of tuberculosis compared to non-tubercu-
losis patients was highest for adenocarcinoma.45 Adenocarcinomas are more slowly 
growing tumors, with a better prognosis than small cell carcinoma and squamous 
cell carcinomas.10, 12-13 Although, in the group with a history of tuberculosis, large cell 
carcinomas and adenocarcinomas were the most common histological types of lung 
cancer, the mortality risk in this group was higher than the risk in the non-tuberculosis 
group, with more small cell carcinomas and squamous cell carcinomas.
We hypothesize that the explanation for the poor survival in the tuberculosis group 
is of immunological origin. After infection with tuberculosis there is an active im-
munological response that may lead to the development of granulomas in the lungs. 
These granulomas contain mycobacteria and numerous lymphoid and myeloid 
cells.15-16 As a response to the presence of mycobacteria, inflammatory cells will 
release factors to eradicate the pathogen and enhance the immune reactions.15-16 
This ongoing reaction to the mycobacterial products can result in an accumulation 
of inflammatory cell types within the infected area in the lung. These inflammatory 
cells produce large amounts of chemokines, cytokines, lytic enzymes and other 
substances, like reactive oxygen species (ROS).15-19 Release of these substances will 
eventually cause DNA damage, genetic alterations of epithelial cells and extensive 
fibrosis of lung tissue.16, 19-21 Tissue repair is associated with cellular proliferation, a 
process that may lead to further DNA mutations. Lung cancers originating from areas 
of pulmonary fibrosis are also referred to as scar carcinomas. Several studies have 
shown that lung cancer patients with a history of pulmonary fibrosis have a decreased 
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survival, despite the fact that lung cancers originating from these areas of fibrosis are 
usually adenocarcinomas, as in our study.22-23
Furthermore, the decreased survival of lung cancer patients with a history of tuber-
culosis could be explained by inflammatory conditions that might not only induce 
malignant cell growth, but may also enhance tumor progression, as described by 
Mantovani et al.23-25 The accumulation of macrophages, myeloid derived-suppressor 
cells (MDSC) and regulatory T cells (Tregs) in these areas impair innate and adaptive 
immune responses against tumor cells via the production of immune suppressive 
cytokines and the induction of T cell tolerance. Pro-inflammatory cytokines, such as 
TNF and IL-6 may lead to up regulated expression of anti-apoptotic genes through the 
NF-κB pathway.26 Moreover, the production of substances, like vascular endothelial 
growth factor (VEGF), matrix metallopeptidases (MMP) by tumor-associated macro-
phages (M2 macrophages) and MDSC contributes to angiogenesis (a common feature 
of tissue repair and essential for tumor growth) and tumor invasion.24-25, 27
With an intact immune system it is estimated that not more than 10% of tubercu-
losis infections will progress to active disease. Impairment of the immune system can 
increase the risk of reactivating a latent tuberculosis, for example in HIV-infected 
patients to up to 10% per year. An intrinsic impairment of the immune system could 
therefore be another explanation for our observation that lung cancer patients with a 
history of tuberculosis have a worse prognosis. Less data support the tumor suppres-
sive effect of a pro-inflammatory status. From animal and human models we know 
that, between other factors, macrophages, CD4+ and CD8+ cells, interferon-γ, tumor 
necrosis factor-α, interleukins and apoptosis of infected cells are important com-
ponents of the immunity to Mycobacterium tuberculosis (M. tuberculosis).15 Macro-
phages play a central role in the immune response to infection with M. tuberculosis. 
Tumor-associated macrophages represent the major inflammatory component of 
tumors, affecting different aspects of tumor growth. Macrophage activation has been 
described as a spectrum, with the 2 extremes described as M1 and M2. Different from 
M2, M1 is associated with tumor suppression. Infection with M. tuberculosis will 
result in a classical M1 activation with cytotoxic activity both to ingested intracellular 
micro-organisms like M. tuberculosis, and to tumor cells. Less M1 activity might result 
in both reactivation of tuberculosis infection and in less cytotoxic antitumor response 
and faster tumor growth. Evidence for this hypothesis comes from studies, which 
found that the presence of a low M1 macrophage density in the tumor is associated 
with an impaired lung cancer prognosis.28-29 This demonstrates that M1 macrophages 
play a pivotal role in the overall survival of cancer.
Because of the prospective cohort design and high participation rate of our study, 
selection and information bias are less likely while we adjusted for most known 
confounders. Our findings cannot be generalized to the total population because all 
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study members were 55 years or older. However, the effect of this restriction is likely 
to be modest as 75-85% of the lung cancer arises in people aged above 55 years.30-31
Notably, we cannot exclude some misclassification of the exposure due to self 
report of tuberculosis. Not all subjects may remember their respiratory tuberculosis, 
or they may be unaware that they have had tuberculosis in the past. Though, we were 
able to confirm eleven out of the thirteen respiratory tuberculosis cases on the basis 
of medical records; for the remaining two cases no data were available. However, 
such non-differential misclassification of exposure is usually random which leads 
to an underestimation of a true association. This might mean that our results are 
conservative.
Another limitation is that we did not have data available on the prognostic factor 
WHO performance status of our lung cancer cases. It would have been preferential if 
we could have adjusted for this aspect in the survival comparison, because together 
with disease stage it is one of the most important prognostic factors for lung cancer 
survival. However, there is no evidence to assume that a history of tuberculosis at 
least 16 years before lung cancer diagnosis will influence the performance status 
of the patients at time of diagnosis. This is supported by the comparable findings in 
characteristics between the two groups in age at diagnosis, stage of disease, histologi-
cal subtype and pack-years. Therefore, we hypothesize that a history of tuberculosis 
might cause changes in the microenvironment of the lung tissue and that these im-
munological changes lead to a shorter survival of lung cancer.
Unfortunately, we were not aware of the treatment of the patients. However, treat-
ment of lung cancer is rarely curative, and there are no established therapies, which 
convincingly increase survival after adjusting for type and stage of the lung cancer. As 
we adjusted for type and stage, it is not likely that treatment confounded our results.
The number of participants included in the cohort of the Rotterdam Study is large 
(n = 7,983), all patient data are well documented, and the study design is unique for 
world-wide cohorts. However, due to relatively low incidences of both lung cancer 
and tuberculosis in The Netherlands it is not realistic to double or triple this cohort 
to reaffirm our data. Nevertheless, the results obtained were striking in the way that a 
significant correlation between the survival of lung cancer and a history of tubercu-
losis infection was found.
In conclusion, a history of pulmonary tuberculosis seems to be a poor prognostic 
factor for lung cancer survival in Caucasian patients. Because of the low numbers in 
our study, replication of our results in independent cohorts is warranted. Apart from 
epidemiological studies, more research is needed to elicit common immunological 
pathways in the etiology of tuberculosis and lung cancer.
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GENERAL DISCUSSION
This thesis describes the role of early detection of lung cancer by screening programs 
and the influence of the immune system on the course of lung cancer treatment. Sur-
vival of lung cancer can be improved by intervening on two pivotal prognostic fac-tors: 
disease stage and treatment. In the following sections we elaborate on the main findings 
from this thesis and discuss the implications these might have on the detec-tion and 
treatment of lung cancer. At the end we will speculate about future research.
Evaluating the role of lung cancer screening
In the studies described in chapter IV and V, we evaluate the use of lung cancer 
screening programs. As early stages of lung cancer have a better prognosis, early 
diagnosis by screening programs could lead to reduction of lung cancer mortality. 
However, important biases, including lead-time bias, length time bias and overdiag-
nosis should be taken into account (Chapter V).
Recently, the National Lung Screening Trial (NLST)1 showed that lung cancer death 
rates can be reduced by 20% when a high-risk group is screened with a low-dose CT 
scan compared to chest radiography. Because this study used strict inclusion criteria 
we investigated whether the results of the NLST are generalizable (Chapter IV). When 
we applied the relative reduction in mortality in the lung cancer cases found by the 
NLST to the Rotterdam Study, we found different results; a relative reduction in mor-
tality of 20%, as found in the screening trial, would lead to a reduction in mortality 
in the Rotterdam Study population of lung cancer of 6.0%. We therefore concluded 
that screening of lung cancer with the present inclusion criteria reduces lung cancer 
death rate compared to standard of care. But because only a minority of lung cancer 
patients complies with these criteria we should be cautious in generalizing findings 
to the total patient population.
An important aspect that should be considered in generalizing the results of screen-
ing studies is the therapeutic options for patients with a positive screening, as lung 
cancer treatment is an important prognostic factor. In recent years, peri-operative 
mortality has decreased by the introduction of Video Assisted Thoracoscopy (VATS) 
and better peri-operative management.2 Early stage patients who are not eligible for 
surgery are frequently treated with radiotherapy with curative intent.3 Novel radio-
therapy techniques, such as stereotactic ablative radiotherapy do increase survival 
and also adjuvant chemotherapeutic regimens have been shown to increase survival 
especially in resected patients with stage II and IIIA disease. These regimens are 
expensive and therefore the results of the NLST can only be applied to countries with 
health care systems with a quality comparable to the US.4
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Additionally, a concern in lung cancer screening is whether it is ethical to limit 
screening programs to individuals with >30 pack years (PY) of smoking, while ap-
proximately one-third of the population of lung cancer patients has smoked less than 
this threshold.5 Screening programs may therefore unintentionally give the reassur-
ance that there is no need to stop smoking, leading to continuation of smoking.
Also the cost effectiveness of low dose CT screening must be considered. The use 
of three annual CT screenings, the follow-up of the participants and the additional 
clinical procedures in response to positive screening is very expensive: $725,000 
to prevent one death from lung cancer.6 Several research groups modelled the cost-
effectiveness analyses of CT screening with varying conclusions.7,8 Wisnivesky et al.7 
conclude that the cost-effectiveness ratio of a baseline CT scan is within the range 
of clinical practice and health policy acceptability, while Mahadevia et al.8 state 
that lung cancer screening is unlikely to be highly cost-effective, because of the low 
substantial reductions in mortality, low rates of adherence, high rates of overdiag-
nosis, and high costs per screening test. This contradiction should be investigated in 
more detail. The Dutch Belgian lung cancer screening study NELSON will also give 
important information on this.9,10
Taken together, early detection of lung tumors by lung cancer screening programs 
has led to more curative therapeutic options for patients and to a mortality reduction. 
However, results from the trial may only apply to individuals with access to high 
quality lung cancer care. In addition, screening trials for lung cancer only include a 
minority of lung cancer patients as most patients do not comply with these criteria. 
Therefore, clinicians should be cautious in generalizing findings to the total popula-
tion of lung cancer patients, as until now, the use of lung cancer screening in clini-
cal practice may have limitations in reducing lung cancer mortality. Nevertheless, 
screening programs will be very important in improving survival by earlier detection 
and subsequent treatment of lung cancer cases.
The contribution of the immune system in lung cancer
Multiple studies have shown that chronic inflammation predisposes to different forms 
of cancer, including lung cancer.11,12 For instance, it has been shown that the risk of 
developing lung cancer is higher among smokers with COPD compared to smokers 
without COPD.13 In addition, an inflammatory component is present in the micro-
environment of most neoplastic tissues, including those not causally related to an 
obvious inflammatory process.12,14,15
In recent years it has been established that the immune system plays an important 
role in carcinogenesis and makes an essential contribution to the anti-tumor effects 
of traditional therapies.16-18 Modulation of the patient’s immune system by immuno-
therapy either as monotherapy or combined with conventional cancer treatments 
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offers the prospect of tailoring treatments much more precisely and could lead to 
a better response to treatment and overall survival of NSCLC patients.19 However, 
before immunotherapy can be successfully applied to lung cancer patients, more 
knowledge about the immune system and cancer-related inflammation is needed.
The tumor environment contains a wide variety of recruited host immune cells. 
These tumor infiltrating immune cells influence anti-tumor responses in opposing 
ways and emerge as critical regulators of tumor growth.20 In this thesis we describe 
that the presence of inflammation, in the form of a history of pulmonary tuberculosis 
may be an important prognostic factor in the survival of lung cancer. We hypothesize 
that the explanation for the poor survival in the tuberculosis group is of immunologi-
cal origin (Chapter X)21; as a response to the presence of mycobacteria, inflammatory 
cells will release factors to eradicate the pathogen and enhance the immune reac-
tions. The eradication may fail in tuberculosis, resulting in ongoing inflammatory 
reactions in the lungs of these patients that can lead to scar formation.22-24 Although 
it is not completely understood what the underlying mechanism for this increased 
risk is, it has been reported that scarring of the lung after tuberculosis predisposes 
to the development of lung cancer in these patients, especially adenocarcinoma.22-24 
We hypothesize this is also caused by the ongoing immune related inflammation 
present in these scares. When a tumor is formed, macrophages, myeloid-derived 
suppressor cells (MDSC) and regulatory T cells (Treg) can accumulate and this can 
lead to impaired innate and adaptive immune responses against tumor cells via the 
production of immune suppressive cytokines and the induction of T cell tolerance.21 
Pro-inflammatory cytokines, such as tumor necrosis factor (TNF) and interleukin (IL)-
6 may lead to up regulated expression of anti-apoptotic genes through the nuclear 
factor kappa beta (NF-κB) pathway.25 Moreover, the production of substances, like 
vascular endothelial growth factor (VEGF), matrix metallopeptidases (MMP) by tumor-
associated macrophages (M2 macrophages) and MDSC contributes to angiogenesis 
(a common feature of tissue repair and essential for tumor growth) and tumor inva-
sion.11,26,27 So, inflammatory conditions might not only induce malignant cell growth, 
but may also enhance tumor progression. Gaining insight into the functions of the 
different immune cells that play a role in lung cancer improves the understanding 
of a substantial part of the mechanisms that regulate lung cancer development and 
progression. In addition, knowledge about these mechanisms could be used to tailor 
lung cancer treatment to a patient’s specific needs and requirements, or to optimize 
the condition of the patient before treatment.
We evaluated the influence of the relevant immunological cell types and their com-
plex and dynamic roles within lung cancer patients (Chapter VI and VII). In this thesis 
we focussed on CD4+ and CD8+ T cells and MDSC, because these cell populations 
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play a pivotal role in the tumor-immunology and the knowledge of the presence and 
functions of these cells in lung cancer patients is still limited.
We showed that there were significant differences in MDSC and lymphocyte popu-
lations between NSCLC patients and healthy controls (Chapter VIII); MDSC levels 
were significantly higher in patients, while CD4+ and CD8+ T cells were significantly 
decreased in lung cancer patients compared to healthy controls. These differences are 
correlated with WHO performance status and stage of the disease. As these two are 
well known prognostic factors in lung cancer, we hypothesize that these cells could 
play an important role in the prognosis of lung cancer patients.
MDSC (Chapter I, VI-IX) consist of a heterogeneous group of immature myeloid 
cells and myeloid progenitor cells that can accumulate under pathological condi-
tions at the tumor site, in the lymphoid organs and in peripheral blood.28,29,30 They 
can suppress T cell responses by different mechanisms, dependent on the context of 
the microenvironment.31 MDSC are characterized by different cell markers, includ-
ing immature myeloid markers and mature myeloid markers, high arginase activity, 
and the production of reactive oxygen species (ROS). Two major subpopulations 
of MDSC were defined based on the difference in expression of CD14: polymor-
phnuclear (PMN) MDSC and monocytic (M) MDSC. PMN-MDSC are character-
ized as CD16low,CD11b+,CD14-,HLA-DR-,CD15+,CD33+ cells, while M-MDSC are 
characterized by CD16low,CD11b+,CD14+,HLA-DR-,CD15+,CD33+.32,33,34 In addition, 
PMN-MDSC and M-MDSC differ in function and quantity; M-MDSC use different 
suppressive mechanisms and are present in much smaller amounts in the peripheral 
blood of non-small cell lung cancer (NSCLC) patients than PMN-MDSC.35
As described above, the characterization of MDSC in humans is challenging be-
cause the lack of specific markers. In chapter VIII we showed that arginase-1 (Arg-1) 
mRNA is mainly produced by PMN-MDSC and the percentage of PMN-MDSC cor-
relates with the Arg-1 levels in the peripheral blood of NSCLC patients. We anticipate 
that Arg-1 is a useful surrogate marker for the frequency of MDSC in PBMC. This 
could have major advantages; first, Arg-1 mRNA expression levels can be measured 
by qRT-PCR instead of six markers that are needed to identify the MDSC population 
with flowcytometry. As a result, no expensive flowcytometers are needed to investi-
gate this cell population. Next to this, Arg-1 mRNA can be reliably measured in the 
PBMC fraction that is snap frozen after ficoll isolation. This is useful for large patient 
multicenter studies, because measurements can be performed at later time points, 
in contrast to measuring MDSC by flowcytometry freshly. This might be a valuable 
tool to reduce the day-to-day variability. The question remains however, how these 
immunological data can be used to improve the response to treatment and the related 
survival.
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Cancer immunotherapy attempts to activate the host’s immune system to recognize 
and destroy small tumor nodules or the residual lung cancer cells that conventional 
therapy misses (Chapter I, VI and IX). CD8+ T cells play an important role in attacking 
tumor cells, and therefore many immunomodulatory agents and technologies intend 
to increase the number and efficacy of CD8+ T cells. Immunotherapy that tries to 
activate CD8+ T cells is presumed to be most effective in early stages of lung cancer.36 
This raises the question whether this could be based on immunological differences 
between the stages of lung cancer or the WHO performance status categories.
We showed that MDSC were significantly correlated with stage of disease. In ad-
dition, CD3+ and CD8+ T cells are significantly negatively correlated with WHO 
performance status, while the number of PMN-MDSC showed a strong positive trend 
(Chapter IX). We also provided evidence that there are large differences within stage 
IV lung cancer patients, for instance, in the numbers of CD8+ T cells (Chapter IX). 
Some patients have similar levels of CD8+ T cells as healthy controls, while other 
patients have a significantly decreased number of CD8+ T cells. So, there are large 
differences in the composition of the immune system between patients of different 
stages and even between patients within the same stage. These findings might explain 
why only a small group of lung cancer patients at present benefit from immuno-
therapy. We anticipate that immunotherapeutic agents that attempt to activate CD8+ 
T cells are only effective when CD8+ T cells are actively present.37 Patients with a 
limited number of CD8+ T cells, which are mostly seen in advanced stage patients, 
are not likely to benefit from these therapies without modulation of the immune 
system beforehand.
The response to immunotherapy probably depends on the composition of the im-
mune system, which is different in every patient. Therefore, we anticipate that the 
response to treatment could improve significantly if the treatment is tuned to the 
cellular make-up of each patient individually. This patient tailored treatment should 
be based on both tumoral and immunological characteristics, rather than by the stage 
of disease or histology. This individualized, multi-targeted approach will be able to 
restore the balance towards efficacious antitumor responses that can improve the 
overall survival of lung cancer patients. We anticipate that the future standard of care 
of lung cancer patients will imply patient tailored conventional therapy combined 
with immunotherapeutic approaches based on the patient’s unique immune profile, 
driven by the increasing understanding of the immune system in the cancer cell’s 
environment.
This pre-treatment profile should divide patients into different groups based on the 
immunological cells types that are present in the host. Immunological cells that can 
be taken into account are CD4+ and CD8+ T cells and MDSC. CD4+ T-helper cells 
and CD8+ cytotoxic T cells represent the strong effectors of the adaptive immune 
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response against cancer and MDSC are immature immunosuppressive cells that 
inhibit T cells and are involved in angiogenesis and metastatic spread. Patients with 
low T cell numbers would benefit if they first receive dendritic cell vaccination or 
adoptive T-cell transfer therapy to increase the number of T cells, resulting in a better 
response to immunomodulatory antibodies, such as anti-CTLA-4 (ipilimumab).37 In 
patients with high MDSC levels, immunotherapy will probably have better results 
when MDSC first eliminated for instance with drugs like gemcitabine, 5-fluorouracil 
(5FU) or VEGF blockers (sunitinib).38-40 In addition, the suppressive mechanisms of 
MDSC could be targeted by arginase-1 inhibitors, for instance N-Hydroxy-nor-L-Arg 
(Nor-NOHA), N-Hydroxy-L-Arg (NOHA) or by exogenous L-arginine suppletion41-43, 
or by blocking the ILT3 receptor44 (Chapter VII and VIII). These inhibitors are already 
used in the clinic in other diseases; it has been shown that arginase inhibition mark-
edly improves endothelial function in patients with coronay artery disease and type 2 
diabetes mellitus.45 In addition, by giving lung cancer patients Nor-NOHA or NOHA, 
the suppressive effects of MDSC will be attenuated. This could lead to a stronger 
attack of the tumor cells by the immune system.
We hypothesize that these interventions are likely to increase the number of 
patients that will benefit from immunotherapy. Additionally, we think that these pre-
treatment profiles could also play an important role in conventional therapy, as the 
response to conventional therapy depends on the composition of the immune cells. 
Future research should be focused on which therapy has the best results based on the 
presence and activity of immune cells of the host.
Methodological considerations
The patients described in this thesis are embedded in three studies: the Rotterdam-
study, the NVALT-12 study and the Intrimthom study. These studies are subject to 
common issues that reflect on the validity and generalizability. The Rotterdam Study46 
is a population-based prospective cohort study in Rotterdam, the Netherlands. All 
inhabitants of the Rotterdam suburb Ommoord aged ≥ 55 years were invited to 
participate in the study, which started with a baseline interview between July 1989 
and July 1993. Of the 10,215 eligible subjects, 7,983 (78%) agreed to participate.46 
Because of the prospective design and high participation rate of this study, selection 
and information bias are not likely. However, the findings from this study cannot 
be generalized to the total population because all study members were 55 years or 
older. The NVALT-12 study (trial number NCT01171170) is a randomized phase II 
multicentre study on the effect of a nitroglycerin patch or placebo in patients with 
stage IV non-squamous NSCLC treated with carboplatin paclitaxel and bevacizumab. 
Blood samples were collected at baseline from 185 patients who were not applicable 
for treatment with curative intent. The Intrimthom study (trial number MEC-2010-384) 
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is a multicenter observational study that aims to investigate the influence of immune 
cells in thoracic malignancies as a prognostic factor. Patients from the NVALT-12 
study and the Intrimthom study are also part of a selected population, i.e. stage IV 
non-squamous NSCLC and patients treated in an academic hospital, respectively. 
Selection bias and generalization bias are likely in both studies.
Cell populations were measured on a LSRII flowcytometer. This technology allows 
to identify a large number of different cells in one sample, based on a particle’s 
relative size, relative granularity or internal complexity, and relative fluorescence 
intensity. Because the different blood samples were not processed on the same day, 
there is the possibility of day-to-day variability of the instrument. Nevertheless, this 
variability is reduced by acalibration on a regular basis..
Implications for further research
We have stored blood and serum samples at three different time points of the patients 
from the NVALT-12 study: before chemotherapy (baseline), and after the first cycle 
and second cycle of chemotherapy. In the INTRIMTHOM study, bloodsamples are 
collected in patients before and after curative interventions and afterwards every 3 
months. A next step in evaluating the influence of the immune system in lung cancer 
is to investigate the presence of other cell types and cytokines rather than T cells and 
MDSC, and to correlate the immunological data with the response to treatment and 
the survival of the patients. In addition, a more detailed subdivision of T cells, for 
instance, Treg or the state (e.g. exhaustion) of T cells will be made. Moreover, it would 
be interesting to investigate whether adapting the composition of the immune system 
of a lung cancer patient by immunotherapy based on a pre-treatment profile will lead 
to an increased survival.
Other cell types and cytokines
As described in chapter V, there are many different cell types that play an important 
role in lung cancer. Investigating other relevant cell types, for instance Treg and TAM 
could be valuable for fine-tuning patient tailored treatment. In future research it 
would be interesting to investigate whether there are differences in these cell types 
between lung cancer patients and if these cells correlate with survival.
Treg are a subpopulation of CD4+CD25+ T lymphocytes that are produced dur-
ing maturation in the thymus (natural Treg) or induced in the periphery (induced 
Treg). They are further characterized by the expression of forkhead box P3 (Foxp3), 
glucocorticoid-induced TNF-receptor-related-protein (GITR), lymphocyte activation 
gene-3 (LAG-3), cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), and a down-
regulation of CD127 (IL-7R). Tregs are increased in tumor tissue47 and in peripheral 
blood48 of NSCLC patients compared to healthy volunteers. This increase in Tregs was 
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found to promote tumor growth and correlated with lymph node metastasis.14,49 There 
is substantial interest for overcoming Treg induced immunesuppressision to enhance 
the efficacy of cancer immunotherapy.
Macrophages in tumors are usually referred to as TAM and their presence can be 
substantial (10 to 65% of the tumor stroma). Macrophages can be divided into M1 
macrophages (‘classical activation’) or M2 macrophages (‘alternative activation’).50 
M1 macrophages attract and activate cells of the adaptive immune system and have 
anti-tumor and tissue destructive activity, while the M2 phenotype is more focused 
on tissue repair, tissue remodeling and immunoregulation. In a small tumor, the TAM 
mainly consist of M1 macrophages and later in the process, when the tumor starts 
to invade and vascularize, there is a skewing towards the M2 phenotype. It has been 
shown that high numbers of M1 macrophages infiltrating the tumor are correlated 
with improved survival.51,52 There are currently no agents for clinical use available 
that specifically target TAM53 but several strategies are currently investigated that at-
tack macrophages at several levels. For example, blockade of factors and cytokines 
secreted by tumor or immune cells to limit the induction of M2 macrophages are 
investigated, these include inhibition of prostaglandin E2 synthesis (cox-2 inhibitor)54, 
anti-CCL2, anti-TGF-b, anti-IL-6 (Siltuximab)55, agonists for TLR and NOD (Imiqui-
mod)56, however this results in loss of typical M2 markers but not their function.57 
It has been shown that inhibiting IκB kinase (IKK) reprogrammes the M2 phenotype 
to the M1 subset.58,59 Also CD40 therapy seems to skews tumor-infiltrating (not the 
resident) macrophages towards the M1 phenotype.60 The effects of bisphosphonates 
(Zoledronic acid) on TAM were investigated.61,62 Influencing the attraction, the polar-
ization or the activation of M2 macrophages may improve survival when combined 
with standard or other immunotherapeutic regimens.
Tumor cells produce an offensive repertoire of factors that can lead to the recruit-
ment and activation of bone-marrow-derived cells to the tumor site. In general, these 
include cytokines, chemokines, such as transforming growth factor (TGF), tumor 
necrosis factor (TNF), vascular endothelial growth factor (VEGF), platelet derived 
growth factor (PDGF), insulin-like growth factor (IGF), and different types of inter-
leukins (IL)-1, IL-6 and IL-8, amongst many others.20 In future research it would be 
interesting to see whether there are differences in these cytokines and chemokines 
in the serum of lung cancer patients compared to healthy controls. These factors can 
easily be detected by enzyme-linked immuno sorbent assay (ELISA). In addition, it 
would be interesting to see whether these factors are correlated with the different 
immune cells and other prognostic factors.
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Response to treatment and survival of patients in the nVaLT12 study
Response to treatment and survival data from the NVALT12 study are not available 
yet. As soon as these are available, the different pivotal immunological cell types and 
relevant cytokines of the lung cancer patients are correlated with outcome (response 
to treatment and/or overall survival).
Predicting the best treatment per patient and the survival based on the immunologi-
cal profile could lead to major advances in survival. Next to this, patients who are 
less likely to get a response to treatment will not unnecessarily undergo treatment and 
suffer from the associated side effects.
Future recommendations to improve lung cancer survival
Modulation of the patient’s immune system by immunotherapy either as monotherapy 
or combined with conventional cancer treatments offers the prospect of tailoring 
treatments much more precisely and could lead to a better response to treatment and 
overall survival of NSCLC patients. Still, patients will have the best prognosis if lung 
cancer is detected in an early stage of disease, for instance by lung cancer screening. 
In this early stage, the immune system of the patient is mostly still sufficient and can 
more easily be adapted by therapy.
The ideal situation would be that a high-risk population for the development of 
lung cancer is identified by non-invasive screening of lung cancer biomarkers, for 
instance by blood biomarkers, exhaled breath measurements or sputum cytology, 
which should be highly sensitive and specific. Currently these are not available. If this 
screening is positive a CT scan should be made. When subjects are diagnosed with 
lung cancer they will get a pre-treatment profile based on the composition of different 
immunological cells. Based on the stage of disease and this immunological profile, 
the best patient-tailored treatment will be chosen.
The future of cancer therapy lies in combining conventional treatment, such as sur-
gery, radiotherapy or systemic therapy, with immunotherapy in order to consolidate 
the effects of the single treatment. This will evolve alongside our understanding of 
the immune system in tumorogenesis. We hypothesize that conventional treatments 
options combined with immunotherapy, based on a pretreatment profile of the im-
mune system of the host, could be a valuable tool to increase the survival of patients 
with early stage NSCLC.
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SUMMARY
- Lung cancer screenings trials only apply to individuals with access to high quality 
lung cancer care. In addition, screening trials for lung cancer only include a mi-
nority of lung cancer patients, as most patients do not comply with the inclusion 
criteria of these screening trials.
- At this point the use of lung cancer screening in clinical practice has limitations in 
reducing lung cancer mortality, as the results of screenings trials are not generaliz-
able to the total population of smokers.
- The presence of a history of pulmonary tuberculosis is an important prognostic 
factor in the survival of lung cancer and plays an important role in lung cancer 
development.
- The immune system differs significantly between lung cancer patients and healthy 
controls.
- The frequencies of immune cells are correlated to the two most important prog-
nostic factors: disease stage and world health organisation (WHO) performance 
status.
- Arginase-1 (Arg-1) mRNA is mainly expressed by myeloid derived suppressor 
cells MDSC and the level of Arg-1 mRNA in peripheral blood mononuclear cells 
(PBMC) correlates with the frequency of MDSC in PBMC. qRT-PCR on Arg-1 might 
therefore be useful as an alternative method to determine the levels of PMN-
MDSC in peripheral blood of cancer patients.
- The immune suppressive immunoglobulin-like transcript (ILT)-3 is present on 
MDSC. This protein is an attractive candidate for immunotherapy, as blocking 
ILT3 could inhibit the immune suppressive functions of ILT3.
- The limited number of advanced lung cancer patients that benefit from treatment 
is probably caused by the coherence of a restricted number of CD8+ T cells and 
an increased number of MDSC caused by the tumor microenvironment.
- Patient tailored immunotherapies that optimize tumor-specific CD8+ T cell func-
tion seem an essential step to increase the efficacy of lung cancer treatment. It 
might be advantageous to make a pre-treatment prediction based on an immuno-
logical profile which patients are likely to benefit from therapy.
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LONGKANKER
Longkanker is de belangrijkste oorzaak van overlijden door kanker. De 5-jaars over-
leving is slechts 16%. Een van de redenen voor deze uiterst slechte overleving is dat 
longkanker meestal wordt gediagnosticeerd in een vergevorderd stadium. Dit komt 
door het gebrek aan klinische symptomen, zoals vermoeidheid, kortademigheid, 
pijnklachten en bloed ophoesten tijdens de vroege stadia. Daarnaast is longkanker 
vaak een agressieve ziekte, waardoor er snel metastasen ontstaan. Gemetastaseerde 
longkanker is momenteel een ongeneeslijke ziekte. De standaard chemotherapie 
leidt slechts tot geringe verbetering in de overleving. Minder dan 30% van de patiën-
ten met gevorderde stadia van longkanker hebben een response op chemotherapie. 
Terwijl dit de meest effectieve eerstelijns behandeling van uitgezaaide longkanker 
is. Er zijn twee belangrijke vormen van longkanker: niet-kleincellig long carcinoom 
(NSCLC) (85% van alle gevallen) en klein-cellig longcarcinoom (15% van alle geval-
len). NSCLC kan worden onderverdeeld in vier histologische subtypes: plaveiselcel 
carcinoom, adenocarcinoom, grootcellig longcarcinoom en ongedifferentieerd 
longcarcinoom. Roken is de belangrijkste risicofactor voor longkanker. Plaveiselcel 
carcinoom is een aan roken gerelateerde kanker die zich meestal ontwikkelt vanuit 
bronchiale epitheelcellen in de centrale luchtwegen. Indien longkanker zich ontwik-
keld bij mensen die niet gerookt hebben is dit meestal adenocarcinoom, en ontwik-
kelt de kanker zich vanuit basale bronchiale cellen.
Sreeningsonderzoek naar longkanker
Longkanker screeningsonderzoek is erop gericht om longkanker in een vroeg sta-
dium op te sporen, zodat de kans op genezing groter is en zo te zorgen voor een 
verbetering van de overleving van deze ziekte. Er zijn verschillende studies uitge-
voerd die onderzochten of longkanker vroegtijdig te diagnosticeren is met behulp 
van een röntgenfoto (X-thorax), maar helaas werd daar geen overlevingsvoordeel 
mee aangetoond. De meest recente studies onderzoeken met behulp van een lage 
stralingsdosis computed tomografie (CT) scan of longkanker eerder opgespoord kan 
worden, waardoor de kans op overleving vergroot wordt. Een CT scan is gevoeliger 
voor het detecteren van afwijkingen in de thorax dan een standaard röntgenfoto.
Bij screeningsonderzoeken moet echter altijd rekening worden gehouden met bias 
(vertekening van de resultaten). Belangrijke vormen van bias zijn: length time bias en 
lead time bias. Length time bias kan optreden wanneer er, door langdurige screenings 
intervallen, vooral ziekten worden gedetecteerd met een langdurig ziektebeloop. Als 
er door het screenen dan alleen langzaam groeiende longtumoren worden gevon-
den kan dit de indruk geven dat screening leidt tot een verbetering in overleving, 
terwijl dit in werkelijkheid niet zo hoeft te zijn. Lead time bias is als een ziekte door 
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screening in een vroeger stadium wordt gedetecteerd zonder dat dit uiteindelijk leidt 
tot een verbetering van de overleving. De overlevingsduur is dan wel toegenomen, 
maar dit komt niet doordat het beloop van de ziekte is veranderd, maar puur omdat 
de tumor eerder is gediagnosticeerd. Daarnaast kan er door screening overdiagnose 
optreden. Dit houdt in dat er een ziekte wordt gediagnosticeerd door screening, die 
anders tijdens het leven van de patiënt nooit voor symptomen zou zorgen en de 
patiënt door andere oorzaken overlijdt. Deze detectie kan echter wel zorgen voor 
veel psychologische stress en onnodige behandeling van de patiënt, waardoor de 
kosten voor de gezondheidszorg verder stijgen.
De Nationale Lung Screening Trial (NLST) heeft echter recent aangetoond dat een 
jaarlijkse low-dose CT screening van een op roken en leeftijd geselecteerde groep 
mensen voor een daling in longkanker sterfte zorgt van 20%. Dit komt doordat de 
longkanker door de screening in een vroeger stadium wordt ontdekt en dan nog 
curatief behandeld kan worden, waardoor de overleving toeneemt. De resultaten van 
het onderzoek zijn echter door strenge selectiecriteria van de NLST alleen toepasbaar 
op een geselecteerde groep mensen. De bevindingen kunnen daarom op dit moment 
nog niet gegeneraliseerd worden naar de hele bevolking. Desondanks zorgen long-
kanker screeningsprogramma’s voor een vroege detectie van de ziekte en kunnen ze 
in de toekomst erg belangrijk zijn om de longkanker overleving te verbeteren.
Longkanker en het immuunsysteem
Bij het ontstaan van kanker speelt het immuunsysteem een belangrijke rol. Verschil-
lende onderzoeken hebben aangetoond dat chronische ontsteking een risicofactor 
vormt voor het ontstaan van longkanker. Het risico op het krijgen van longkanker 
onder rokende mensen met chronisch obstructieve longziekten (COPD) is bijvoor-
beeld veel hoger dan bij rokende mensen zonder COPD.
Daarnaast is het aangetoond dat de tumoromgeving veel verschillende immuuncel-
len bevat. Een deel van deze immuuncellen, zoals cytotoxische T cellen (CTLs) kun-
nen de tumor aanvallen, waardoor deze kleiner wordt of zelfs helemaal weggaat. 
Er zijn echter ook immuuncellen, zoals myeloid derived suppressor cells (MDSC), 
die er voor kunnen zorgen dat de tumor sneller kan groeien, doordat deze cellen 
bijvoorbeeld de CTLs onderdrukken.
Inzicht krijgen in de functies van de verschillende immuuncellen die een belangrijke 
rol spelen bij longkanker kan ervoor zorgen dat de mechanismes verantwoordelijk 
voor het ontstaan van longkanker en de progressie van de ziekte duidelijker worden. 
Deze kennis kan vervolgens gebruikt worden om de behandeling van longkanker 
meer af te stemmen op de individuele kenmerken van de patiënt, waardoor de kans 
op respons op de behandeling groter wordt en de overleving toeneemt.
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Doel van het onderzoek
In de afgelopen decennia is er veel onderzoek gedaan naar het verlagen van de sterfte 
van patiënten met longkanker. Helaas is tot nu toe de verbetering in de lange termijn 
overleving beperkt en heeft longkanker nog steeds een slechte prognose. Recente 
onderzoeken tonen een afname aan van de sterfte aan longkanker door screenings-
programma’s. Het is niet de verwachting dat door verbeteringen in de standaard 
behandelingsstrategieën de prognose van longkanker patiënten veel zal verbeteren. 
Daarnaast zou modulatie van het immuunsysteem van een longkanker patiënt door 
immunotherapie, hetzij als monotherapie of in combinatie met conventionele kan-
kerbehandelingen, kunnen leiden tot een meer nauwkeurigere behandeling. Dit zou 
kunnen zorgen voor een betere respons op de behandeling en een langere overleving.
Aangezien slechts kleine verbeteringen in overleving kunnen worden verwacht 
in uitgezaaide longkanker met gebruik van de al bestaande therapieën, zou meer 
onderzoek gericht moeten zijn op longkanker screeningprogramma’s en tevens voor 
de patiënt toegesneden immunotherapie met of zonder conventionele therapieën.
Dit proefschrift evalueert de rol van het immuunsysteem in longkanker patiënten. 
Bovendien wordt de rol van CT screening, om zo longkankerpatiënten in een vroeg 
stadium te detecteren, onderzocht. Het doel van het onderzoek was om te zoeken 
naar nieuwe strategieën om de overleving van longkanker te verbeteren.
Het proefschrift is opgedeeld in vier delen. Het eerste deel beschrijft longkanker in 
het algemeen. Het tweede deel gaat over longkanker screening en het derde deel 
over de rol van het immuunsysteem bij longkanker. Het vierde deel bestaat uit de 
discussie en samenvatting.
Hoofdstuk I geeft een algemene introductie over longkanker, het ontstaan van de 
ziekte en de therapieën. Daarnaast wordt besproken hoe longkanker screening en 
modulatie van het immuunsysteem mogelijk kunnen zorgen voor een verbeterde 
overleving van longkanker patiënten.
Hoofdstuk II geeft het overzicht en het doel van dit proefschrift weer. De over-
leving van longkanker is de afgelopen jaren niet erg verbeterd. In hoofdstuk III 
wordt beschreven dat de overleving van longkanker verbeterd kan worden door 
longkanker in een vroeger stadium op te sporen en de behandeling aan te passen aan 
de immuuncellen die aanwezig zijn in de patiënt. Wij vinden dat er daarom meer 
onderzoek zou moeten worden gedaan op het vlak van longkanker screening en 
patiënt-specifieke therapie.
In Hoofdstuk IV worden de inclusiecriteria van longkanker screening besproken en 
wordt onderzoek verricht naar de generaliseerbaarheid van de bevindingen van grote 
screenings studies naar de totale populatie van longkanker patiënten. Wij vonden dat 
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als de inclusie criteria van de NLST worden toegepast op de mensen uit de Rotterdam 
Studie, dat de afname in sterfte door screening echter lager is dan de getallen van de 
NLST. De 20% afname in longkanker sterfte is alleen toepasbaar in een geselecteerde 
groep mensen die al een sterk verhoogd risico hebben voordat ze gescreend worden.
Hoofdstuk V bediscussieert het belang van longkanker screening in meer detail. 
Longkanker screening heeft als voordeel dat je de kanker in een vroeg stadium de-
tecteert, maar belangrijk is om rekening te houden dat de resultaten van verbeterde 
overleving door screening niet in elk land  gelden. Dit is onder andere afhankelijk 
van de gezondheidszorg in dat land. Daarom moeten artsen voorzichtig zijn om de 
bevinding dat screening leidt tot verbeterde overleving van longkanker te generali-
seren.
Hoofdstuk VI geeft een overzicht van de relevante immunologische celtypes die een 
rol spelen in longkanker. De rol van het immuunsysteem is tweezijdig. Aan de ene 
kant zorgt het immuunsysteem ervoor dat kanker cellen aangevallen worden, maar 
het immuunsysteem kan er ook voor zorgen dat de kanker juist sneller kan groeien. 
Dit hoofdstuk beschrijft de complexe en dynamische functies van de celtypes in de 
tumor omgeving.
In hoofdstuk VII beschrijven we een nieuwe receptor op een belangrijke populatie 
van immuun onderdrukkende cellen, MDSC. Deze receptor heet immunoglobulin-
like transtcript-3 (ILT3) en speelt een rol in onderdrukking van T cellen. Wij denken 
dat de ILT3 receptor een van de vele manieren is waarmee een MDSC een immuun-
suppressief is wat ertoe kan leiden dat een tumor sneller groeit.
Hoofdstuk VIII  beschrijft de immunologische karakteristieken van 185 gemetasta-
seerde NSCLC patiënten. We beschrijven de karakterisatie en optimale omstandighe-
den om MDSC te analyseren en we onderzochten hun aanwezigheid en functie in 
het perifere bloed van gemetastaseerde NSCLC patiënten. We vonden dat MDSC 
verhoogd voorkomen, terwijl T-cellen juist in verlaagd voorkomen in het bloed van 
longkanker patienten in vergelijking met gezonde mensen. Daarnaast vonden we dat 
de hoeveelheid messenger-RNA van Arginase-1 correleert met het aantal MDSC dat 
aanwezig is in het bloed van longkanker patienten.
In hoofdstuk IX onderzoeken we het verband tussen de belangrijkste immuuncel-
len, zoals CD8+ T cellen en MDSC in het perifere bloed van longkanker patiënten 
met verschillende ziekte stadia. We vonden verschillen in immuuncel samenstelling 
tussen patiënten met verschillende ziekte stadia van longkanker en patiënten uit 
verschillende categorieën van de WHO performance status.
Hoofdstuk X beschrijft de relatie tussen ontsteking en longkanker. We vonden dat 
longtuberculose een onafhankelijke risicofactor is voor de overleving van longkanker. 
Mensen die in het verleden tuberculose hebben doorgemaakt hebben een slechtere 
overleving van hun longkanker.
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Concluderend, de overlevingskansen van longkanker patiënten zijn op dit moment 
nog steeds laag. Twee manieren waarmee de overleving verbeterd zou kunnen wor-
den is door het eerder opsporen van longkanker, bijvoorbeeld met behulp van CT 
screeningsprogramma’s of door de therapie beter op elke patiënt afzonderlijk af te 
stemmen op basis van de verschillen in samenstelling van het immuunsysteem.
Longkanker screeningsprogramma’s dragen bij tot een verbetering in overleving 
van longkanker in landen met een goede kwaliteit van zorg. Op dit moment is echter 
alleen onderzoek gedaan naar de effectiviteit van screening bij een geselecteerde 
groep mensen en zijn de resultaten van de onderzoeken dus niet toepasbaar op de 
hele bevolking.
Daarnaast hebben we aangetoond dat er grote verschillen zijn in de samenstelling 
van het immuunsysteem tussen gezonde mensen en longkanker patiënten. Deze 
verschillen zie je ook binnen longkanker patiënten van verschillende stadia en zelfs 
binnen de groep van stadium IV longkanker patiënten. We hebben laten zien dat 
Arg-1 mRNA een goede maat is om het aantal MDSC in het bloed van longkanker 
patiënten te meten. Daarnaast beschrijven we dat de immuunsuppressieve receptor 
ILT3 verhoogd aanwezig is op de MDSC van longkanker patiënten in vergelijking met 
gezonde controles.
Er zijn maar weinig patiënten met gemetastaseerde ziekte die reageren op immuun-
therapie. Dit komt waarschijnlijk doordat ze een laag aantal CD8+ T cellen en een 
hoog aantal MDSC in hun bloed hebben.
Wij denken dat het maken van een immunologisch profiel voordat de patiënt be-
handeld wordt kan zorgen voor een voor de patiënt meer specifieke behandeling, 
waardoor de kans dat de behandeling aanslaat toeneemt.
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